U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Belinson S, Chopra R, Yang Y, et al. Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec. (Comparative Effectiveness Reviews, No. 93.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer

Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer [Internet].

Show details

Appendix FExcluded Studies

Level 1, Form Title Screening, Does the article report primary data? -> Exclude (No)

  1. Ong SY. Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature. Ann Acad Med Singapore. 2003;32(2):205–11. [PubMed: 12772524]
  2. Van Laethem JL. Adjuvant treatment for colorectal cancer. Acta Gastroenterol Belg. 2001;64(3):263–7. [PubMed: 11680045]
  3. Eadens MJ, Grothey A. Curable metastatic colorectal cancer. Curr Oncol Rep. 2011;13(3):168–76. [PubMed: 21298372]
  4. Gravante G, Overton J, Sorge R, Bhardwaj N, Metcalfe MS, Lloyd DM, Dennison AR. Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies. J Gastrointest Surg. 2011;15(2):378–87. [PubMed: 21061179]
  5. Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int. 2010;107(19):335–42. [PMC free article: PMC2881614] [PubMed: 20532128]
  6. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J. 2010;16(3):235–40. [PubMed: 20526102]
  7. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78(3–4):237–48. [PubMed: 20523084]
  8. Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010;22(4):364–73. [PubMed: 20520544]
  9. Kulaylat MN, Gibbs JF. Thermoablation of colorectal liver metastasis. J Surg Oncol. 2010;101(8):699–705. [PubMed: 20512946]
  10. Kulaylat MN, Gibbs JF. Regional treatment of colorectal liver metastasis. J Surg Oncol. 2010;101(8):693–8. [PubMed: 20512945]
  11. Pwint TP, Midgley R, Kerr DJ. Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol. 2010;37(2):149–59. [PubMed: 20494707]
  12. Ammori JB, Kemeny NE. Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. Semin Oncol. 2010;37(2):139–48. [PubMed: 20494706]
  13. Crocetti L, Lencioni R. Radiofrequency ablation of pulmonary tumors. Eur J Radiol. 2010;75(1):23–7. [PubMed: 20452739]
  14. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer. 2010;102(9):1313–8. [PMC free article: PMC2865767] [PubMed: 20424612]
  15. Alexander HR Jr, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J. 2010;16(2):132–41. [PubMed: 20404610]
  16. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J. 2010;16(2):125–31. [PubMed: 20404609]
  17. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J. 2010;16(2):111–7. [PubMed: 20404607]
  18. Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28(13):2300–9. [PubMed: 20368552]
  19. Robinson S, Manas DM, Pedley I, Mann D, White SA. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol. 2011;20(2):57–72. [PubMed: 19962301]
  20. Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Rev Anticancer Ther. 2009;9(12):1829–47. [PubMed: 19954294]
  21. Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33(1):11–7. [PMC free article: PMC2816824] [PubMed: 19924474]
  22. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009;6(12):687–97. [PubMed: 19884901]
  23. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB 3rd. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493–508. [PubMed: 19841322]
  24. Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer. 2009;45(17):2947–59. [PubMed: 19773153]
  25. Power DG, Kemeny NE. Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? Ann Surg. 2009;250(4):654–5. author reply 655. [PubMed: 19730229]
  26. Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol. 2009;15(31):3855–64. [PMC free article: PMC2731247] [PubMed: 19701965]
  27. Shimada H, Tanaka K, Endou I, Ichikawa Y. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg. 2009;394(6):973–83. [PubMed: 19582473]
  28. Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009;16(9):2385–90. [PubMed: 19554377]
  29. Bhardwaj N, Strickland AD, Ahmad F, Dennison AR, Lloyd DM. Liver ablation techniques: a review. Surg Endosc. 2010;24(2):254–65. [PubMed: 19554370]
  30. Van De Wiele C, Defreyne L, Peeters M, Lambert B. Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors. Q J Nucl Med Mol Imaging. 2009;53(3):317–24. [PubMed: 19521311]
  31. Reddy SK, Barbas AS, Clary BM. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? Ann Surg Oncol. 2009;16(9):2395–410. [PubMed: 19506963]
  32. Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep. 2009;11(3):200–8. [PubMed: 19336012]
  33. Vriens D, de Geus-Oei LF, van der Graaf WT, Oyen WJ. Tailoring therapy in colorectal cancer by PET-CT. Q J Nucl Med Mol Imaging. 2009;53(2):224–44. [PubMed: 19293770]
  34. Bellavance EC, Alexander HR Jr. TNF-based isolated hepatic perfusion. Front Biosci. 2009;14:1771–84. [PubMed: 19273161]
  35. Boutros C, Somasundar P, Garrean S, Saied A, Espat NJ. Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis. Surg Oncol. 2010;19(1):e22–32. [PubMed: 19268571]
  36. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10(3):278–86. [PubMed: 19261256]
  37. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–92. [PubMed: 19153115]
  38. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials. 2009;4(1):56–62. [PubMed: 19149763]
  39. Alberts SR. Updated options for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7 Suppl 2:S58–62. [PubMed: 19064408]
  40. Lencioni R, Crocetti L, Pina MC, Cioni D. Percutaneous image-guided radiofrequency ablation of liver tumors. Abdom Imaging. 2009;34(5):547–56. [PubMed: 19030918]
  41. Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg. 2008;15(6):570–80. [PubMed: 18987925]
  42. Gasent Blesa JM, Dawson LA. Options for radiotherapy in the treatment of liver metastases. Clin Transl Oncol. 2008;10(10):638–45. [PubMed: 18940744]
  43. Gillams A. Tumour ablation: current role in the liver, kidney, lung and bone. Cancer Imaging. 2008;8(Spec No A):S1–5. [PMC free article: PMC2582496] [PubMed: 18852074]
  44. Garcea G, Ong SL, Maddern GJ. Inoperable colorectal liver metastases: a declining entity? Eur J Cancer. 2008;44(17):2555–72. [PubMed: 18755585]
  45. Jones A, Alexander HR Jr. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. Surg Oncol Clin N Am. 2008;17(4):857–76. x. [PubMed: 18722923]
  46. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008;21(12):1107–17. [PubMed: 18713148]
  47. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti MA, Bilchik AJ, Van Cutsem EJ, Chiang JM, D’Angelica MI. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol. 2008;26(29):4828–33. [PubMed: 18711170]
  48. Power DG, Healey-Bird BR, Kemeny NE. Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7(4):247–59. [PubMed: 18650193]
  49. Jagad RB, Koshariya M, Kawamoto J, Papastratis P, Kefalourous H, Patris V, Tzouma C, Lygidakis NJ. Management of rectal cancer: strategies and controversies. Hepatogastroenterology. 2008;55(81):82–92. [PubMed: 18507084]
  50. Pozzo C, Barone C, Kemeny NE. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treat Rev. 2008;34(4):293–301. [PubMed: 18291590]
  51. Topkan E, Onal HC, Yavuz MN. Managing liver metastases with conformal radiation therapy. J Support Oncol. 2008;6(1):9–13. 15. [PubMed: 18257395]
  52. de Jong KP. Review article: Multimodality treatment of liver metastases increases suitability for surgical treatment. Aliment Pharmacol Ther. 2007;26 Suppl 2:161–9. [PubMed: 18081659]
  53. Andromanakos N, Filippou D, Papadopoulos V, Kouraklis G, Christianakis E, Kostakis A. New concepts in the therapeutic options of liver metastases from colorectal cancer. J BUON. 2007;12(4):445–52. [PubMed: 18067201]
  54. Evans J. Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). Eur J Surg Oncol. 2007;33 Suppl 2:S64–75. [PubMed: 18061390]
  55. Schirmang TC, Dupuy DE. Image-guided thermal ablation of nonresectable hepatic tumors using the Cool-Tip radiofrequency ablation system. Expert Rev Med Devices. 2007;4(6):803–14. [PubMed: 18035946]
  56. Ganeshan A, Upponi S, Hon LQ, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol. 2008;19(5):847–51. [PubMed: 18029972]
  57. Small R, Lubezky N, Ben-Haim M. Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J. 2007;9(10):742–7. [PubMed: 17987765]
  58. Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol. 2007;33 Suppl 2:S42–51. [PubMed: 17981429]
  59. Benoist S, Nordlinger B. Neoadjuvant treatment before resection of liver metastases. Eur J Surg Oncol. 2007;33 Suppl 2:S35–41. [PubMed: 17981428]
  60. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol. 2007;10(1):38–46. [PubMed: 17980317]
  61. Lim E, Thomson BN, Heinze S, Chao M, Gunawardana D, Gibbs P. Optimizing the approach to patients with potentially resectable liver metastases from colorectal cancer. ANZ J Surg. 2007;77(11):941–7. [PubMed: 17931254]
  62. White RR, Jarnagin WR. The role of aggressive regional therapy for colorectal liver metastases. Cancer Invest. 2007;25(6):458–63. [PubMed: 17882658]
  63. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12(7):825–39. [PubMed: 17673614]
  64. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11(8):1057–77. [PubMed: 17530336]
  65. Leen E, Horgan PG. Radiofrequency ablation of colorectal liver metastases. Surg Oncol. 2007;16(1):47–51. [PubMed: 17499499]
  66. Bremers AJ, Ruers TJ. Prudent application of radiofrequency ablation in resectable colorectal liver metastasis. Eur J Surg Oncol. 2007;33(6):752–6. [PubMed: 17408907]
  67. Moosmann N, Heinemann V. Cetuximab in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther. 2007;7(2):243–56. [PubMed: 17250462]
  68. Abdulaal Y, Ross P, Heaton N. Intra arterial hepatic chemotherapy for unresectable colorectal metastases: (review). Gulf J Oncolog. 2007;1(1):77–92. [PubMed: 20084717]
  69. Tanabe KK. New techniques of liver surgery. Semin Oncol 2006. 33(6 Suppl 11):S39–41. [PubMed: 17178285]
  70. Golling M, Bechstein W. Surgical resection of colorectal liver metastases--the current standard therapy (review). Rozhl Chir. 2006;85(8):381–9. [PubMed: 17144119]
  71. Schumacher G, Eisele R, Spinelli A, Neuhaus P. The surgical approach for radiofrequency ablation of liver tumors. Recent Results Cancer Res. 2006;167:53–68. [PubMed: 17044296]
  72. McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg. 2006;93(10):1192–201. [PubMed: 16983740]
  73. Fahy BN, Jarnagin WR. Evolving techniques in the treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, microwave coagulation, hepatic arterial chemotherapy, indications and contraindications for resection, role of transplantation, and timing of chemotherapy. Surg Clin North Am. 2006;86(4):1005–22. [PubMed: 16905421]
  74. Lise M, Pilati P, Da Pian P, Mocellin S, Nitti D, Corazzino S. Treatment options for liver metastases from colorectal cancer. J Exp Clin Cancer Res. 2003;22(4 Suppl):149–56. [PubMed: 16767922]
  75. Tol J, Punt CJ. Treatment of liver metastases from colorectal cancer. Neth J Med. 2006;64(5):133–5. [PubMed: 16702610]
  76. Chua YJ, Cunningham D. Neoadjuvant treatment of unresectable liver metastases from colorectal cancer. Clin Colorectal Cancer. 2006;5(6):405–12. [PubMed: 16635279]
  77. Gibson TB. Radiofrequency ablation for patients with colorectal cancer and unresectable liver metastasis. Clin Colorectal Cancer. 2006;5(5):318–20. [PubMed: 16512988]
  78. Feliberti EC, Wagman LD. Radiofrequency ablation of liver metastases from colorectal carcinoma. Cancer Control. 2006;13(1):48–51. [PubMed: 16508626]
  79. Homsi J, Garrett CR. Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer. Cancer Control. 2006;13(1):42–7. [PubMed: 16508625]
  80. Vauthey JN, Zorzi D, Pawlik TM. Making unresectable hepatic colorectal metastases resectable--does it work? Semin Oncol. 2005;32(6 Suppl 9):S118–22. [PubMed: 16399448]
  81. Curley SA. Outcomes after surgical treatment of colorectal cancer liver metastases. Semin Oncol. 2005;32(6 Suppl 9):S109–11. [PubMed: 16399446]
  82. Vauthey JN, Abdalla EK. Unresectable hepatic colorectal metastases: need for new surgical strategies. Ann Surg Oncol. 2006;13(1):5–6. [PubMed: 16372151]
  83. Vibert E, Canedo L, Adam R. Strategies to treat primary unresectable colorectal liver metastases. Semin Oncol. 2005;32(6 Suppl 8):33–9. [PubMed: 16360011]
  84. Shimada H, Tanaka K, Matsuo K, Togo S. Treatment for multiple bilobar liver metastases of colorectal cancer. Langenbecks Arch Surg. 2006;391(2):130–42. [PubMed: 16320065]
  85. Ruers TJ, de Jong KP, Ijzermans JN. Radiofrequency for the treatment of liver tumours. Dig Surg. 2005;22(4):245–53. [PubMed: 16174981]
  86. Wang P, Chen Z, Huang WX, Liu LM. Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: a literature review of randomized control trials. World J Gastroenterol. 2005;11(25):3817–22. [PMC free article: PMC4504878] [PubMed: 15991275]
  87. Lise M, Mocellin S, Pilati P, Nitti D. Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Front Biosci. 2005;10:3042–57. [PubMed: 15970559]
  88. Gillams AR. The use of radiofrequency in cancer. Br J Cancer. 2005;92(10):1825–9. [PMC free article: PMC2361772] [PubMed: 15870717]
  89. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23(9):2038–48. [PubMed: 15774795]
  90. Ruan DT, Warren RS. Liver-directed therapies in colorectal cancer. Semin Oncol. 2005;32(1):85–94. [PubMed: 15726510]
  91. Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005;56:139–56. [PubMed: 15660506]
  92. Grover A, Alexander HR Jr. The past decade of experience with isolated hepatic perfusion. Oncologist. 2004;9(6):653–64. [PubMed: 15561809]
  93. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol. 2004;15(10):1453–9. [PubMed: 15367403]
  94. Barber FD, Mavligit G, Kurzrock R. Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev. 2004;30(5):425–36. [PubMed: 15245775]
  95. Whisenant J, Venook A. Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer. Oncology (Williston Park). 2004;18(6):762–8. discussion 769–73. [PubMed: 15214595]
  96. van Laarhoven HW, Punt CJ. Systemic treatment of advanced colorectal carcinoma. Eur J Gastroenterol Hepatol. 2004;16(3):283–9. [PubMed: 15195891]
  97. Berr F. Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis. 2004;24(2):177–87. [PubMed: 15192790]
  98. Dawson LA, Lawrence TS. The role of radiotherapy in the treatment of liver metastases. Cancer J. 2004;10(2):139–44. [PubMed: 15130273]
  99. Elaraj DM, Alexander HR. Current role of hepatic artery infusion and isolated liver perfusion for the treatment of colorectal cancer liver metastases. Cancer J. 2004;10(2):128–38. [PubMed: 15130272]
  100. Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am. 2004;84(2):659–71. [PubMed: 15062667]
  101. Elias D, de Baere T, Sideris L, Ducreux M. Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surg Clin North Am. 2004;84(2):607–25. [PubMed: 15062664]
  102. Folprecht G, Kohne CH. The role of new agents in the treatment of colorectal cancer. Oncology. 2004;66(1):1–17. [PubMed: 15031593]
  103. Pasetto LM, Rossi E, Paris MK, Lonardi S, Monfardini S. Common management of primary rectal carcinoma in patients with stage IV disease at the diagnosis. Anticancer Res. 2003;23(6D):4999–5004. [PubMed: 14981958]
  104. Subar DA, Sheen AJ, Sherlock DJ. Cryoablation for liver tumors - is there clinical utility? MedGenMed. 2003;5(4):19. [PubMed: 14745366]
  105. Rhim H, Dodd GD 3rd, Chintapalli KN, Wood BJ, Dupuy DE, Hvizda JL, Sewell PE, Goldberg SN. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications. Radiographics. 2004;24(1):41–52. [PubMed: 14730035]
  106. Pasetto LM, Rossi E, Monfardini S. Liver metastases of colorectal cancer: medical treatments. Anticancer Res. 2003;23(5b):4245–56. [PubMed: 14666634]
  107. Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist. 2003;8(6):553–66. [PubMed: 14657534]
  108. Donckier V, Van Laethem JL, Ickx B, Van Gansbeke D, Goldman S, Gelin M. Local ablative treatments for liver metastases: the current situation. Acta Chir Belg. 2003;103(5):452–7. [PubMed: 14653027]
  109. Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol. 2003;21(4):249–55. [PubMed: 14648782]
  110. Eriguchi M, Levi F, Hisa T, Yanagie H, Nonaka Y, Takeda Y. Chronotherapy for cancer. Biomed Pharmacother. 2003;57(Suppl 1):92s–95s. [PubMed: 14572683]
  111. Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg. 2003;20(6):481–96. [PubMed: 13679642]
  112. Nikfarjam M, Christophi C. Interstitial laser thermotherapy for liver tumours. Br J Surg. 2003;90(9):1033–47. [PubMed: 12945069]
  113. Nordlinger B, Peschaud F, Malafosse R. Resection of liver metastases from colorectal cancer—how can we improve results? Colorectal Dis. 2003;5(5):515–7. [PubMed: 12925092]
  114. Krastev Z, Koltchakov V, Tomov B, Koten JW. Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2. Hepatogastroenterology. 2003;50(52):1006–16. [PubMed: 12845968]
  115. Hehr T, Wust P, Bamberg M, Budach W. Current and potential role of thermoradiotherapy for solid tumours. Onkologie. 2003;26(3):295–302. [PubMed: 12845217]
  116. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol. 2003;14 Suppl 2:ii49–55. [PubMed: 12810459]
  117. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14(Suppl 2):ii13–6. [PubMed: 12810452]
  118. Fusai G, Davidson BR. Management of colorectal liver metastases. Colorectal Dis. 2003;5(1):2–23. [PubMed: 12780921]
  119. Meyers MO, Sasson AR, Sigurdson ER. Locoregional strategies for colorectal hepatic metastases. Clin Colorectal Cancer. 2003;3(1):34–44. [PubMed: 12777190]
  120. Lau TN, Lo RH, Tan BS. Colorectal hepatic metastases: Role of radiofrequency ablation. Ann Acad Med Singapore. 2003;32(2):212–8. [PubMed: 12772525]
  121. Scaife CL, Curley SA. Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. Surg Oncol Clin N Am. 2003;12(1):243–55. [PubMed: 12735142]
  122. Adam R, Huguet E, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth H. Hepatic resection after down-staging of unresectable hepatic colorectal metastases. Surg Oncol Clin N Am. 2003;12(1):211–20. xii. [PubMed: 12735139]
  123. Bilchik AJ. Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update. Surg Oncol Clin N Am. 2003;12(1):193–210. [PubMed: 12735138]
  124. Braccia DP, Heffernan N. Surgical and ablative modalities for the treatment of colorectal cancer metastatic to the liver. Clin J Oncol Nurs. 2003;7(2):178–84. [PubMed: 12696214]
  125. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol. 2003;9(2):193–200. [PMC free article: PMC4611310] [PubMed: 12532430]
  126. Muller H, Hilger R. Curative and palliative aspects of regional chemotherapy in combination with surgery. Support Care Cancer. 2003;11(1):1–10. [PubMed: 12527948]
  127. Topham C, Adam R. Oncosurgery: a new reality in metastatic colorectal carcinoma. Semin Oncol. 2002;29(5 Suppl 15):3–10. [PubMed: 12422303]
  128. Canter RJ, Williams NN. Surgical treatment of colon and rectal cancer. Hematol Oncol Clin North Am. 2002;16(4):907–26. [PubMed: 12418055]
  129. Skitzki JJ, Chang AE. Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol. 2002;11(3):123–35. [PubMed: 12356508]
  130. Kemeny M. Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer. Cancer J. 2002;8 Suppl 1:S82–8. [PubMed: 12075705]
  131. Alexander HR Jr. Surgical approaches to liver metastases. Cancer J. 2002;8 Suppl 1:S68–81. [PubMed: 12075704]
  132. Casper ES. Gastrointestinal stromal tumors. Curr Treat Options Oncol. 2000;1(3):267–73. [PubMed: 12057170]
  133. Liu LX, Jiang HC, Piao DX. Radiofrequence ablation of liver cancers. World J Gastroenterol. 2002;8(3):393–9. [PMC free article: PMC4656408] [PubMed: 12046057]
  134. Bleiberg H, Hendlisz A. Advanced colorectal cancer treatment in Europe: what have we achieved? Anticancer Drugs. 2002;13(5):461–71. [PubMed: 12045457]
  135. Ku Y, Tominaga M, Iwasaki T, Fukumoto T, Kuroda Y. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. Int J Clin Oncol. 2002;7(2):82–90. [PubMed: 12018114]
  136. Carroll NM, Alexander HR Jr. Isolation perfusion of the liver. Cancer J. 2002;8(2):181–93. [PubMed: 12004803]
  137. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38(7):1023–33. [PubMed: 11978527]
  138. Giacchetti S. Chronotherapy of colorectal cancer. Chronobiol Int. 2002;19(1):207–19. [PubMed: 11962676]
  139. Weinreich DM, Alexander HR. Transarterial perfusion of liver metastases. Semin Oncol. 2002;29(2):136–44. [PubMed: 11951211]
  140. Makin GB, Breen DJ, Monson JR. The impact of new technology on surgery for colorectal cancer. World J Gastroenterol. 2001;7(5):612–21. [PMC free article: PMC4695561] [PubMed: 11819841]
  141. Biasco G, Gallerani E. Treatment of liver metastases from colorectal cancer: what is the best approach today? Dig Liver Dis. 2001;33(5):438–44. [PubMed: 11529658]
  142. Malafosse R, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12(7):887–94. [PubMed: 11521792]
  143. Moroz P, Jones SK, Gray BN. Status of hyperthermia in the treatment of advanced liver cancer. J Surg Oncol. 2001;77(4):259–69. [PubMed: 11473375]
  144. Neeleman N, Wobbes T, Jager GJ, Ruers TJ. Cryosurgery as treatment modality for colorectal liver metastases. Hepatogastroenterology. 2001;48(38):325–9. [PubMed: 11379301]
  145. Fiorentini G, Poddie DB, Cantore M, Giovanis P, Guadagni S, De Giorgi U, Cariello A, Dazzi C, Turci D. Locoregional therapy for liver metastases from colorectal cancer: the possibilities of intraarterial chemotherapy, and new hepatic-directed modalities. Hepatogastroenterology. 2001;48(38):305–12. [PubMed: 11379296]
  146. Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg. 2001;25(6):685–8. [PubMed: 11376397]
  147. Brouquet A, Andreou A, Vauthey JN. The management of solitary colorectal liver metastases. Surgeon. 2011;9(5):265–72. [PubMed: 21843821]
  148. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin Oncol. 2011;38(4):552–60. [PubMed: 21810514]
  149. Tanaka K, Ichikawa Y, Endo I. Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol. 2011 [PubMed: 21786210]
  150. Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, Poston G. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. 2011;13(9):e252–65. [PubMed: 21689362]
  151. de Baere T, Deschamps F. Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging. 2011;36(6):661–70. [PubMed: 21681492]
  152. Curing patients with liver metastases from colorectal cancer. Drug Ther Bull. 2011;49(4):42–5. quiz i–ii. [PubMed: 21467575]
  153. Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol. 2010;2(10):380–9. [PMC free article: PMC2999674] [PubMed: 21160889]
  154. Power DG, Kemeny NE. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol. 2011;79(3):251–64. [PubMed: 20970353]
  155. Carter S, Martin Ii RC. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford). 2009;11(7):541–50. [PMC free article: PMC2785948] [PubMed: 20495705]
  156. Dudeck O, Ricke J. Advances in regional chemotherapy of the liver. Expert Opinion on Drug Delivery. 2011;8(8):1057–1069. [PubMed: 21506902]
  157. Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Current Opinion in Investigational Drugs. 2009;10(12):1372–1382. [PubMed: 19943208]
  158. Geschwind JFH. The future of catheter guided cancer therapy. CardioVascular and Interventional Radiology. 2009;32:262–264.
  159. Abdalla EK. Surgical management of colorectal liver metastases. Community Oncology. 2009;6(8):349–357.
  160. D’Angelica M, Fong Y, DeMatteo RP, Jarnagin WR. Hepatic arterial infusion chemotherapy for metatstases from colorectal cancer: Is it really the end of an era? Journal of Clinical Oncology. 2008;26(16):2788–2789. [PubMed: 18509192]
  161. Mocellin S, Nitti D. In reply. Journal of Clinical Oncology. 2008;26(16):2789–2790. [PubMed: 18509192]
  162. Choti MA. New paradigm in the treatment of hepatic colorectal metastases: A surgeon’s perspective. Community Oncology. 2008;5(6 SUPPL 6):9–14.
  163. Arciero CA, Sigurdson ER. Diagnosis and Treatment of Metastatic Disease to the Liver. Seminars in Oncology. 2008;35(2):147–159. [PubMed: 18396200]
  164. Kennedy G, Nelson H. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases - Invited critique. Archives of Surgery. 2008;143(4):358. [PubMed: 18427022]
  165. Kohne CH. Neoadjuvant chemotherapy in a patient with metastatic colorectal cancer. Community Oncology. 2007;4(5 SUPPL):8–11.
  166. Bartlett DL, Berlin J, Lauwers GY, Messersmith WA, Petrelli NJ, Venook AP. Chemotherapy and regional therapy of hepatic colorectal metastases: Expert consensus statement. Annals of Surgical Oncology. 2006;13(10):1284–1292. [PubMed: 16955384]
  167. Tanabe KK. Emerging therapies for metastatic carcinoma to the liver. Community Oncology. 2006;3(9):567–573.
  168. Kerr DJ. Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?: Commentary. Nature Clinical Practice Oncology. 2006;3(9):480–481. [PubMed: 16955085]
  169. Garrean S, Joseph Espat N. Yttrium-90 internal radiation therapy for hepatic malignancy. Surgical Oncology. 2005;14(4):179–193. [PubMed: 16527479]
  170. Meriggi F. Surgical therapy of colorectal metastases—State of the art. Romanian Journal of Gastroenterology. 2004;13(3):233–235. [PubMed: 15470537]
  171. Ruan DT, Warren RS. Palliative techniques for hepatic cancer. Surgical Oncology Clinics of North America. 2004;13(3):505–516. [PubMed: 15236732]
  172. Adam R. Current surgical strategies for the treatment of colorectal cancer liver metastases. European Journal of Cancer, Supplement. 2004;2(7):21–26.
  173. Ku Y, Tominaga M, Iwasaki T, Fukumoto T, Kusunoki N, Ogata S, Kuroda Y. Regional treatment for unresectable malignant hepatic tumors: An overview of isolated hepatic perfusion. Chirurgische Gastroenterologie Interdisziplinar. 2003;19(4):370–376.
  174. Frich L, Mala T, Edwin B, Gladhaug I, Mathisen O, Bergan A. Malignant liver tumors. A review of current surgical treatment options. Experience from a Norwegian hepatobiliary center. Gastroenterologia Polska. 2003;10(4):349–356.
  175. Alberts S, Poston G. OncoSurge: A strategy for long-term survival in metastatic colorectal cancer. Colorectal Disease. 2003;5(SUPPL 3):20–28. [PubMed: 23573557]
  176. Venook AP. Induction therapy in patients with metastatic colorectal cancer. Seminars in Oncology. 2003;30(4 SUPPL 12):25–29. [PubMed: 14508724]
  177. Kemeny NE, Galsky M. Hepatic artery infusion for liver metastases. Seminars in Colon and Rectal Surgery. 2002;13(4):293–304.
  178. Gigot JF, Goffette P. Commentary. HPB. 2002;4(1):[d]27–28.
  179. Bartlett DL. Systemic chemotherapy of liver tumors. Seminars in Surgical Oncology. 2000;19(2):116–124. [PubMed: 11126376]
  180. Alexander HR Jr, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5(5):416–424. [PubMed: 11040278]
  181. Lorenz M, Heinrich S, Staib-Sebler E, Gog C, Vetter G, Petrowsky H, Muller HH. Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. Swiss Surgery. 2000;6(1):11–22. [PubMed: 10709432]

Level 1, Form Title Screening, Are the participants in the article h... -> Exclude (No)

  1. Ortega-Deballon P, Facy O, Consolo D, Magnin G, Tixier H, Simonet M, Rat P, Chauffert B. Hypoxic single-pass isolated hepatic perfusion of hypotonic Cisplatin: safety study in the pig. Ann Surg Oncol. 2010;17(3):898–906. [PubMed: 19859770]
  2. Cai SR, Garbow JR, Culverhouse R, Church RD, Zhang W, Shannon WD, McLeod HL. A mouse model for developing treatment for secondary liver tumors. Int J Oncol. 2005;27(1):113–20. [PubMed: 15942650]

Level 1, Form Title Screening, Is unresectable colorectal cancer the... -> Exclude (No)

  1. Goere D, Gaujoux S, Deschamp F, Dumont F, Souadka A, Dromain C, Ducreux M, Elias D. Patients operated on for initially unresectable colorectal liver metastases with missing metastases experience a favorable long-term outcome. Ann Surg. 2011;254(1):114–8. [PubMed: 21516034]
  2. Karasaki T, Sano K, Takamoto T, Kinoshita H, Tateishi R, Takemura T, Makuuchi M. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports. Hepatogastroenterology. 2010;57(104):1526–8. [PubMed: 21443115]
  3. Vasic L. Osteolysis of hand bones due to metastatic deposits from colon cancer--a case report. Med Pregl. 2010;63(9–10):719–22. [PubMed: 21443059]
  4. Azevedo CR, Cezana L, Moraes ES, Begnami MD, Paiva TF Junior, Dettino AL, Fanelli MF. Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report. Sao Paulo Med J. 2010;128(6):371–4. [PubMed: 21308162]
  5. Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. Jpn J Clin Oncol. 2011;41(4):490–7. [PubMed: 21303790]
  6. Tanaka K, Nojiri K, Kumamoto T, Takeda K, Endo I. R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy. Eur J Surg Oncol. 2011;37(4):336–43. [PubMed: 21277151]
  7. Kim HC, Chung JW, An S, Seong NJ, Son KR, Jae HJ, Park JH. Transarterial chemoembolization of a colic branch of the superior mesenteric artery in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(1):47–54. [PubMed: 21195900]
  8. Deschamps F, Rao P, Teriitehau C, Hakime A, Malka D, Boige V, Ducreux M, Elias D, Goere D, de Baere T. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol. 2010;21(11):1681–8. [PubMed: 21029950]
  9. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer. 2010;103(10):1542–7. [PMC free article: PMC2990583] [PubMed: 20959822]
  10. Sakamoto Y, Fujita S, Akasu T, Nara S, Esaki M, Shimada K, Yamamoto S, Moriya Y, Kosuge T. Is surgical resection justified for stage IV colorectal cancer patients having bilobar hepatic metastases?--an analysis of survival of 77 patients undergoing hepatectomy. J Surg Oncol. 2010;102(7):784–8. [PubMed: 20872814]
  11. Chua TC, Bester L, Akther J, Morris DL. Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. Anticancer Res. 2010;30(7):3005–7. [PubMed: 20683046]
  12. Li WH, Peng JJ, Xiang JQ, Chen W, Cai SJ, Zhang W. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. World J Gastroenterol. 2010;16(26):3318–24. [PMC free article: PMC2900725] [PubMed: 20614489]
  13. Bower M, Metzger T, Robbins K, Tomalty D, Valek V, Boudny J, Andrasina T, Tatum C, Martin RC. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford). 2010;12(1):31–6. [PMC free article: PMC2814401] [PubMed: 20495642]
  14. Pini S, Pinto C, Angelelli B, Giampalma E, Blotta A, Di Fabio F, Santini D, Golfieri R, Martoni AA. Multimodal sequential approach in colorectal cancer liver metastases: hepatic resection after yttrium-90 selective internal radiation therapy and cetuximab rescue treatment. Tumori. 2010;96(1):157–9. [PubMed: 20437875]
  15. Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, Okabe H, Baba Y, Kinoshita K, Akira C, Watanebe M, Takamori H, Baba H. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res. 2010;30(3):1015–20. [PubMed: 20393029]
  16. Tochetto SM, Rezai P, Rezvani M, Nikolaidis P, Berggruen S, Atassi B, Salem R, Yaghmai V. Does multidetector CT attenuation change in colon cancer liver metastases treated with 90Y help predict metabolic activity at FDG PET? Radiology. 2010;255(1):164–72. [PubMed: 20308454]
  17. Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T, Hayashi H, Okabe H, Ootao R, Watanabe M, Takamori H, Iyama K, Baba H. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. Int J Clin Oncol. 2010;15(3):263–70. [PubMed: 20238233]
  18. Goere D, Deshaies I, de Baere T, Boige V, Malka D, Dumont F, Dromain C, Ducreux M, Elias D. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251(4):686–91. [PubMed: 20224373]
  19. Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG. Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor? World J Surg. 2010;34(5):1102–8. [PubMed: 20177683]
  20. Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. Jpn J Clin Oncol. 2010;40(4):360–4. [PubMed: 20085906]
  21. Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–44. [PMC free article: PMC4139149] [PubMed: 19952320]
  22. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):38–47. [PubMed: 19942479]
  23. Karoui M, Soprani A, Charachon A, Delbaldo C, Vigano L, Luciani A, Cherqui D. Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36(1):58–64. [PubMed: 19926243]
  24. Muneoka K, Shirai Y, Sasaki M, Wakai T, Sakata J, Hatakeyama K. Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX). Int J Clin Oncol. 2009;14(5):457–9. [PubMed: 19856057]
  25. Takakura Y, Ikeda S, Yoshimitsu M, Hinoi T, Sumitani D, Takeda H, Kawaguchi Y, Shimomura M, Tokunaga M, Okajima M, Ohdan H. Retroperitoneal abscess complicated with necrotizing fasciitis of the thigh in a patient with sigmoid colon cancer. World J Surg Oncol. 2009;7:74. [PMC free article: PMC2762971] [PubMed: 19811627]
  26. Shinjo T, Kondo Y, Harada K, Yamazaki J, Okada M. Treatment of malignant enterovesical fistula with octreotide. J Palliat Med. 2009;12(10):965–7. [PubMed: 19807246]
  27. Whitney R, Tatum C, Hahl M, Ellis S, Scoggins CR, McMasters K, Martin RC. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J Surg Res. 2011;166(2):236–40. [PubMed: 19691985]
  28. Chiappa A, Bertani E, Makuuchi M, Zbar AP, Contino G, Viale G, Pruneri G, Bellomi M, Della Vigna P, Zampino MG, Fazio N, Travaini ML, Trifiro G, Corbellini C, Andreoni B. Neoadjuvant chemotherapy followed by hepatectomy for primarily resectable colorectal cancer liver metastases. Hepatogastroenterology. 2009;56(91–92):829–34. [PubMed: 19621711]
  29. Fujimoto Y, Akasu T, Yamamoto S, Fujita S, Moriya Y. Long-term results of hepatectomy after hepatic arterial infusion chemotherapy for initially unresectable hepatic colorectal metastases. J Gastrointest Surg. 2009;13(9):1643–50. [PubMed: 19582514]
  30. Mailey B, Truong C, Artinyan A, Khalili J, Sanchez-Luege N, Denitz J, Marx H, Wagman LD, Kim J. Surgical resection of primary and metastatic hepatic malignancies following portal vein embolization. J Surg Oncol. 2009;100(3):184–90. [PubMed: 19572328]
  31. Okoshi K, Nagayama S, Furu M, Mori Y, Yoshizawa A, Toguchida J, Sakai Y. A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6. Jpn J Clin Oncol. 2009;39(8):528–33. [PubMed: 19491084]
  32. Zonta A, Pinelli T, Prati U, Roveda L, Ferrari C, Clerici AM, Zonta C, Mazzini G, Dionigi P, Altieri S, Bortolussi S, Bruschi P, Fossati F. Extra-corporeal liver BNCT for the treatment of diffuse metastases: what was learned and what is still to be learned. Appl Radiat Isot. 2009;67(7–8 Suppl):S67–75. [PubMed: 19394837]
  33. Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer. 2009;9:120. [PMC free article: PMC2678276] [PubMed: 19386096]
  34. Cardoso J, Nievas S, Pereira M, Schwint A, Trivillin V, Pozzi E, Heber E, Monti Hughes A, Sanchez P, Bumaschny E, Itoiz M, Liberman S. Boron biodistribution study in colorectal liver metastases patients in Argentina. Appl Radiat Isot. 2009;67(7–8 Suppl):S76–9. [PubMed: 19375931]
  35. Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Nordlinger B. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145(4):362–71. [PubMed: 19303984]
  36. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5. [PubMed: 19247029]
  37. Hsu CW, King TM, Lin CH, Wang HT, Ou WC, Wang JH. Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis. Int J Colorectal Dis. 2009;24(4):377–83. [PubMed: 19116722]
  38. Komatsu S, Sonoyama T, Ochiai T, Ichikawa D, Ikoma H, Okamura H, Otsuji E. Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy. Int J Clin Oncol. 2008;13(6):567–70. [PubMed: 19093189]
  39. Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, Azoulay D, Bismuth H, Castaing D, Adam R. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248(6):994–1005. [PubMed: 19092344]
  40. Pamecha V, Nedjat-Shokouhi B, Gurusamy K, Glantzounis GK, Sharma D, Davidson BR. Prospective evaluation of two-stage hepatectomy combined with selective portal vein embolisation and systemic chemotherapy for patients with unresectable bilobar colorectal liver metastases. Dig Surg. 2008;25(5):387–93. [PubMed: 19033722]
  41. Huh JW, Park YA, Jung EJ, Lee KY, Kwon JE, Sohn SK. Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. J Korean Med Sci. 2008;23(5):916–9. [PMC free article: PMC2579999] [PubMed: 18955806]
  42. Bara T, Bancu S, Gyorgy-Fazahas I, Muresan M, Bara T Jr, Podeanu D, Muresan S. Two-step hepatectomy with right portal branch ligature for a right lobe metastasis. Hepatogastroenterology. 2008;55(85):1370–2. [PubMed: 18795692]
  43. Weihrauch MR, Stippel D, Fries JW, Arnold D, Bovenschulte H, Coutelle O, Hacker U. Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment. Onkologie. 2008;31(8–9):464–7. [PubMed: 18787354]
  44. Trojan J, Lubomierski N, Lehnert T, Engels K, Zeuzem S, Bechstein WO. Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. Z Gastroenterol. 2008;46(8):776–9. [PubMed: 18759201]
  45. Bara T, Bancu S, Gyorgy-Fazakas I, Muresan M, Bara T Jr, Podeanu D, Muresan S. Two-step hepatectomy with right portal branch ligature for a right lobe metastasis. Hepatogastroenterology. 2008;55(84):1071–2. [PubMed: 18705330]
  46. Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P, Renee N, Laurent-Puig P, Chazal M, Benchimol D, Delpero JR, Letoublon C, Pezet D, Seitz JF, Milano G. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14(15):4830–5. [PubMed: 18676755]
  47. Iwanicki-Caron I, Di Fiore F, Roque I, Astruc E, Stetiu M, Duclos A, Tougeron D, Saillard S, Thureau S, Benichou J, Paillot B, Basuyau JP, Michel P. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol. 2008;26(22):3681–6. [PubMed: 18669452]
  48. Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, Ledermann JA, O’Bichere A. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35(2):164–7. [PubMed: 18644695]
  49. Ducreux M, Raoul JL, Marti P, Merrouche Y, Tigaud JM, Rebischung C, Boige V. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Oncology. 2008;74(1–2):17–24. [PubMed: 18536526]
  50. Wong DW, Lupton SC, Bhatt L, Gross L, Taniere P, Peake DR, Spooner D, Geh JI. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience. Clin Oncol (R Coll Radiol). 2008;20(7):517–22. [PubMed: 18514495]
  51. Mueller L, Hillert C, Moller L, Krupski-Berdien G, Rogiers X, Broering DC. Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor? Ann Surg Oncol. 2008;15(7):1908–17. [PubMed: 18459005]
  52. Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, Zamboli A. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352–8. discussion 358. [PubMed: 18427022]
  53. Coskun U, Buyukberber S, Yaman E, Uner A, Er O, Ozkan M, Dikilitas M, Oguz M, Yildiz R, DYB, Kaya AO, Benekli M. Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma. 2008;55(1):65–70. [PubMed: 18190244]
  54. Tsimogiannis KE, Pappas-Gogos GK, Nikas K, Stefanaki-Nikou S, Gossios K, Tsimoyiannis EC. Two-stage surgical treatment of unresectable obstructive rectal cancer with synchronous hepatic metastases. Am Surg. 2007;73(12):1218–23. [PubMed: 18186375]
  55. Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie. 2007;30(12):637–43. [PubMed: 18063876]
  56. Kornprat P, Jarnagin WR, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg. 2007;142(11):1087–92. [PubMed: 18025338]
  57. Iguchi T, Arai Y, Inaba Y, Yamaura H, Sato Y, Miyazaki M, Shimamoto H. Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy in patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer. Cardiovasc Intervent Radiol. 2008;31(1):86–90. [PubMed: 17926088]
  58. Adam R, Aloia T, Levi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M, Castagne V, Azoulay D, Castaing D. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25(29):4593–602. [PubMed: 17925554]
  59. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, McMillan DC. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97(9):1266–70. [PMC free article: PMC2360467] [PubMed: 17923866]
  60. Malik HZ, Farid S, Al-Mukthar A, Anthoney A, Toogood GJ, Lodge JP, Prasad KR. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case-controlled study. Ann Surg Oncol. 2007;14(12):3519–26. [PubMed: 17912590]
  61. Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D’Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97(8):1035–9. [PMC free article: PMC2360439] [PubMed: 17895897]
  62. Karoui M, Charachon A, Delbaldo C, Loriau J, Laurent A, Sobhani I, Tran Van Nhieu J, Delchier JC, Fagniez PL, Piedbois P, Cherqui D. Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration. Arch Surg. 2007;142(7):619–23. discussion 623. [PubMed: 17638798]
  63. Lau WY, Lai EC. Hepatic resection for colorectal liver metastases. Singapore Med J. 2007;48(7):635–9. [PubMed: 17609825]
  64. Olmi S, Scaini A, Cesana G, Dinelli M, Lomazzi A, Croce E. Acute colonic obstruction: endoscopic stenting and laparoscopic resection. Surg Endosc. 2007;21(11):2100–4. [PubMed: 17479321]
  65. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6. [PubMed: 17470860]
  66. Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I, Barone C. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11(3):318–24. [PubMed: 17458605]
  67. Berber E, Siperstein AE. Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc. 2007;21(4):613–8. [PubMed: 17287917]
  68. Takahashi S, Kuroki Y, Nasu K, Nawano S, Konishi M, Nakagohri T, Gotohda N, Saito N, Kinoshita T. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res. 2006;26(6C):4705–11. [PubMed: 17214330]
  69. Baize N, Gerard B, Bleiberg H, Caroli-Bosc F, Berthier F, Legendre H, Pector JC, Hendlisz A. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol Clin Biol. 2006;30(12):1349–53. [PubMed: 17211331]
  70. Minagawa M, Yamamoto J, Miwa S, Sakamoto Y, Kokudo N, Kosuge T, Miyagawa S, Makuuchi M. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. Arch Surg. 2006;141(10):1006–12. discussion 1013. [PubMed: 17043279]
  71. Maluccio MA, Covey AM, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, DeMatteo R, Brown KT. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer. 2006;107(7):1617–23. [PubMed: 16955508]
  72. Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg. 2006;93(8):1001–6. [PubMed: 16739103]
  73. Selzner N, Pestalozzi BC, Kadry Z, Selzner M, Wildermuth S, Clavien PA. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg. 2006;93(5):587–92. [PubMed: 16523448]
  74. Goshen E, Davidson T, Zwas ST, Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat. 2006;5(1):37–43. [PubMed: 16417400]
  75. Elias D, Manganas D, Benizri E, Dufour F, Menegon P, El Harroudi T, de Baere T. Trans-metastasis hepatectomy: results of a 21-case study. Eur J Surg Oncol. 2006;32(2):213–7. [PubMed: 16406854]
  76. Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13(1):58–65. [PubMed: 16372158]
  77. Muneoka K, Shirai Y, Yokoyama N, Wakai T, Hatakeyama K. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine. Int J Clin Oncol. 2005;10(6):441–3. [PubMed: 16369751]
  78. Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, Busquier I, Campos JM, Perez-Enguix D, Balcells M. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5(4):263–7. [PubMed: 16356303]
  79. Elias D, Manganas D, Benizri E, Dufour F, Menegon P, El Harroudi T, de Baere T. The trans-metastasis hepatectomy (through metastases previously ablated with radiofrequency): results of a 13-case study of colorectal cancer. J Surg Oncol. 2006;93(1):8–12. [PubMed: 16353184]
  80. Jiao LR, Navarra G, Weber JC, Havlik R, Nicholls JP, Habib NA. Radiofrequency assisted liver resection—a novel technique. Hepatogastroenterology. 2005;52(66):1685–7. [PubMed: 16334757]
  81. Saif MW, Sellers S, Russo S. Gemcitabine-related radiation recall in a patient with pancreatic cancer. Anticancer Drugs. 2006;17(1):107–11. [PubMed: 16317298]
  82. Stathopoulos GP, Rigatos SK, Stathopoulos JG, Xynotroulas JP, Dimou E. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. Am J Clin Oncol. 2005;28(6):565–9. [PubMed: 16317265]
  83. Ho WM, Ma B, Mok T, Yeo W, Lai P, Lim R, Koh J, Wong YY, King A, Leow CK, Chan AT. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol. 2005;22(3):303–12. [PubMed: 16110141]
  84. Togo S, Nagano Y, Masui H, Tanaka K, Miura Y, Morioka D, Endo I, Sekido H, Ike H, Shimada H. Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology. 2005;52(63):913–9. [PubMed: 15966231]
  85. Elias D, Baton O, Sideris L, Boige V, Malka D, Liberale G, Pocard M, Lasser P. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol. 2005;90(1):36–42. [PubMed: 15786433]
  86. Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF, Findlay BP. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16(3):425–9. [PubMed: 15677624]
  87. Ji ZL, Peng SY, Yuan AJ, Li PJ, Zhang W, Yu Y. Hepatic resection for metastasis from colorectal cancer. Tech Coloproctol. 2004;8 Suppl 1:s47–9. [PubMed: 15655640]
  88. Grobmyer SR, Fong Y, D’Angelica M, Dematteo RP, Blumgart LH, Jarnagin WR. Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases. Arch Surg. 2004;139(12):1326–30. [PubMed: 15611458]
  89. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics. 2004;14(12):785–92. [PubMed: 15608557]
  90. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004;240(6):1037–49. discussion 1049–51. [PMC free article: PMC1356519] [PubMed: 15570209]
  91. Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol. 2004;15(12):1766–72. [PubMed: 15550581]
  92. Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology. 2004;51(60):1788–91. [PubMed: 15532827]
  93. Serralta AS, Sanjuan FR, Moya AH, Orbis FC, Lopez-Andujar R, Pareja EI, Vila JC, Rayon M, Juan MB, Mir JP. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol. 2004;16(11):1237–9. [PubMed: 15489588]
  94. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57. discussion 657–8. [PMC free article: PMC1356466] [PubMed: 15383792]
  95. Garcea G, Polemonivi N, O’Leary E, Lloyd TD, Dennison AR, Berry DP. Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases. Eur J Surg Oncol. 2004;30(7):759–64. [PubMed: 15296990]
  96. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15(6):933–9. [PubMed: 15151951]
  97. Julianov A, Karashmalakov A, Rachkov I, Hristov H. Treatment of colorectal cancer with synchronous bilobar liver metastases with simultaneous bowel and liver resection plus radiofrequency ablation. Hepatogastroenterology. 2004;51(57):643–5. [PubMed: 15143882]
  98. Ho HS, Ong HS. A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). Surg Endosc. 2004;18(2):347. [PubMed: 15106627]
  99. Evrard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot V. Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination. Eur J Surg Oncol. 2004;30(4):399–406. [PubMed: 15063893]
  100. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol. 2004;22(9):1546–52. [PubMed: 15051757]
  101. Elias D, Youssef O, Sideris L, Dromain C, Baton O, Boige V, Ducreux M. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86(1):4–9. [PubMed: 15048673]
  102. Rutkowski P, Nyckowski P, Grzesiakowska U, Nowecki ZI, Nasierowska-Guttmejer A, Pienkowski A, Dudek K, Krawczyk M, Ruka W. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma. 2003;50(6):438–42. [PubMed: 14689066]
  103. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10(9):1059–69. [PMC free article: PMC7101740] [PubMed: 14597445]
  104. Takahashi S, Inoue K, Konishi M, Nakagouri T, Kinoshita T. Prognostic factors for poor survival after repeat hepatectomy in patients with colorectal liver metastases. Surgery. 2003;133(6):627–34. [PubMed: 12796730]
  105. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the "test-of-time approach". Cancer. 2003;97(12):3027–35. [PubMed: 12784338]
  106. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, Hawkins IF, Vauthey JN. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237(5):686–91. discussion 691–3. [PMC free article: PMC1514515] [PubMed: 12724635]
  107. Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, Cady J, Andre T, Gamelin E, de Gramont A. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest. 2003;21(1):14–20. [PubMed: 12643005]
  108. Jaeck D, Bachellier P, Nakano H, Oussoultzoglou E, Weber JC, Wolf P, Greget M. One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg. 2003;185(3):221–9. [PubMed: 12620560]
  109. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M, Ducreux M. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13(1):136–40. [PubMed: 12541121]
  110. Rivoire M, De Cian F, Meeus P, Negrier S, Sebban H, Kaemmerlen P. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95(11):2283–92. [PubMed: 12436433]
  111. Yoshida H, Onda M, Tajiri T, Akimaru K, Takasaki H, Mamada Y, Taniai N, Nakamura Y, Kawano Y, Takahashi T. Successful surgical treatment of peritoneal dissemination of hepatocellular carcinoma. Hepatogastroenterology. 2002;49(48):1663–5. [PubMed: 12397759]
  112. Kornmann M, Link KH. Conversion of locally inoperable primary rectal cancer with multiple liver metastases to an option for cure after local down-staging and hepatic arterial infusion chemotherapy. Langenbecks Arch Surg. 2002;387(2):90–3. [PubMed: 12111261]
  113. Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery. 2002;131(4):433–42. [PubMed: 11935134]
  114. Burke D, Davies MM, Zweit J, Flower MA, Ott RJ, Dworkin MJ, Glover C, McCready VR, Carnochan P, Allen-Mersh TG. Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colorectal liver metastases. Br J Cancer. 2001;85(11):1640–5. [PMC free article: PMC2363967] [PubMed: 11742481]
  115. Tanaka K, Shimada H, Togo S, Ota M, Yamagichi S, Ike H. Is hepatic resection for multiple liver metastases from colorectal carcinoma acceptable treatment? Hepatogastroenterology. 2001;48(39):803–7. [PubMed: 11462928]
  116. Utsunomiya T, Emi Y, Ikejiri K, Suzuki M, Saitsu H, Yakabe S, Nonaka M, Saku M, Yoshida K, Shimada M, Sugimachi K. Retrospective study on the effects of lipiodolization before a potentially curative hepatectomy for colorectal liver metastases: long-term results of a pilot study. Hepatogastroenterology. 2001;48(39):790–3. [PubMed: 11462925]
  117. Mizuno N, Naruse S, Kitagawa M, Ishiguro H, Ito O, Ko SB, Yoshikawa T, Tanahashi C, Ito M, Hayakawa T. Insulinoma with subsequent association of Zollinger-Ellison syndrome. Intern Med. 2001;40(5):386–90. [PubMed: 11393407]
  118. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8(4):347–53. [PubMed: 11352309]
  119. Cha C, Lee FT Jr, Rikkers LF, Niederhuber JE, Nguyen BT, Mahvi DM. Rationale for the combination of cryoablation with surgical resection of hepatic tumors. J Gastrointest Surg. 2001;5(2):206–13. [PubMed: 11331484]
  120. Shankar A, Leonard P, Renaut AJ, Lederman J, Lees WR, Gillams AR, Harrison E, Taylor I. Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl. 2001;83(2):85–8. [PMC free article: PMC2503337] [PubMed: 11320935]
  121. Rosty C, Chazal M, Etienne MC, Letoublon C, Bourgeon A, Delpero JR, Pezet D, Beaune P, Laurent-Puig P, Milano G. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer. 2001;95(3):162–7. [PubMed: 11307149]
  122. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232(6):777–85. [PMC free article: PMC1421270] [PubMed: 11088072]
  123. Hellman P, Andersson M, Rastad J, Juhlin C, Karacagil S, Eriksson B, Skogseid B, Akerstrom G. Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg. 2000;24(11):1353–60. [PubMed: 11038206]
  124. Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, Ellis LM. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000;7(7):490–5. [PubMed: 10947016]
  125. Gardiner MF, Long WB, Haskal ZJ, Lichtenstein GR. Upper gastrointestinal hemorrhage secondary to erosion of a biliary Wallstent in a woman with pancreatic cancer. Endoscopy. 2000;32(8):661–3. [PubMed: 10935800]
  126. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, Lemoine A, Bismuth H. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231(4):480–6. [PMC free article: PMC1421022] [PubMed: 10749607]
  127. Isoniemi H, Osterlund P. Surgery combined with oncological treatments in liver metastases from colorectal cancer. Scand J Surg. 2011;100(1):35–41. [PubMed: 21482503]
  128. Davies JM, Goldberg RM. Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases. J Surg Oncol. 2010;102(8):946–54. [PubMed: 21165997]
  129. Brouquet A, Nordlinger B. Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials. J Surg Oncol. 2010;102(8):932–6. [PubMed: 21165995]
  130. Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer. 2010;10:545. [PMC free article: PMC2958953] [PubMed: 20937118]
  131. Nordlinger B, Vauthey JN, Poston G, Benoist S, Rougier P, Van Cutsem E. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer. 2010;9(4):212–8. [PubMed: 20920992]
  132. Kneuertz PJ, Maithel SK, Staley CA, Kooby DA. Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases. Ann Surg Oncol. 2011;18(1):181–90. [PubMed: 20645011]
  133. Alcala MA Jr, Park K, Yoo J, Lee DH, Park BH, Lee BC, Bartlett DL, Lee YJ. Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors. J Cell Biochem. 2010;110(5):1073–81. [PMC free article: PMC2967443] [PubMed: 20544795]
  134. Nasti G, Ottaiano A, Berretta M, Delrio P, Izzo F, Cassata A, Romano C, Facchini G, Scala D, Mastro A, Romano G, Perri F, Iaffaioli RV. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol. 2010;66(2):209–18. [PubMed: 20333385]
  135. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist. 2009;14(11):1095–105. [PubMed: 19880627]
  136. Popescu I, Alexandrescu S, Croitoru A, Boros M. Strategies to convert to resectability the initially unresectable colorectal liver metastases. Hepatogastroenterology. 2009;56(91–92):739–44. [PubMed: 19621694]
  137. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR, Patel D, D’Angelica M. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71. [PMC free article: PMC3646304] [PubMed: 19470932]
  138. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2008;(2):CD006039. [PubMed: 18425932]
  139. Nordlinger B, Van Cutsem E, Rougier P, Kohne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007;43(14):2037–45. [PubMed: 17766104]
  140. Adam R, Miller R, Pitombo M, Wicherts DA, de Haas RJ, Bitsakou G, Aloia T. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am. 2007;16(3):525–36. viii. [PubMed: 17606192]
  141. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23(28):7125–34. [PubMed: 16192596]
  142. Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta. 2005;357(2):180–3. [PubMed: 15921671]
  143. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311–9. [PubMed: 15870084]
  144. Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Ishizu K, Yasuda S, Makuuchi H, Murayama C. Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis. Jpn J Clin Oncol. 2005;35(1):18–22. [PubMed: 15681599]
  145. Rajan DK, Soulen MC, Clark TW, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Freiman DB. Sarcomas metastatic to the liver: Response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol. 2001;12(2):187–93. [PubMed: 11265882]
  146. Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Desguetz G, Louvet C, Landi B, Tiret E, Sobhani I. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: Results of a multicentric study. Dis Colon Rectum. 2011;54(8):930–8. [PubMed: 21730780]
  147. Maroulis I, Karavias DD, Karavias D. General principles of hepatectomy in colorectal liver metastases. Tech Coloproctol. 2011;15(Suppl 1):1–4. [PubMed: 21887560]
  148. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Annals of Oncology. 2011;22(9):2042–2048. [PubMed: 21285134]
  149. Barra M, Dabasi G, Reismann P, Igaz P, Racz K. A simple semiquantitative technique by analyzing somatostatin receptor scintigraphy to predict therapeutic effect of peptide-receptor-radio-therapy. Nuclear Medicine Review. 2011;14:A5.
  150. Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GISTs). Langenbeck’s Archives of Surgery. 2011;396(6):924.
  151. Wicherts DA, De Haas RJ, Andreani P, Ariche A, Salloum C, Pascal G, Castaing D, Adam R, Azoulay D. Short- and long-term results of extended left hepatectomy for colorectal metastases. HPB. 2011;13(8):536–543. [PMC free article: PMC3163275] [PubMed: 21762296]
  152. Bethke A, Kuhne K, Platzek I, Stroszczynski C. Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography. Cancer Imaging. 2011;11(1):91–99. [PMC free article: PMC3205757] [PubMed: 21771709]
  153. O’Malley M, LaGuardia L, Burke C, Kalady M, Church J. Hepatoblastoma: When to screen? Hereditary Cancer in Clinical Practice. 2011;9:19.
  154. Mirarchi M, De Raffele E, Vaccari S, Cola B. Rescue ultrasonography-guided liver resection after selective yttrium-90 radioembolization in a case of bilobar colorectal liver metastases. HPB. 2011;13:77.
  155. Spelt L, Norman P, Tornqvist L, Tingstedt B, Andersson R. Combined portal embolization and neoadjuvant chemotherapy prior to liver resection for colorerectal liver metastases. HPB. 2011;13:52–53.
  156. Brown RE, Bower MR, Metzger TL, Scoggins CR, McMasters KM, Hahl MJ, Tatum C, Martin RCG. Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: Is it safe? HPB. 2011;13(2):91–95. [PMC free article: PMC3044342] [PubMed: 21241425]
  157. Jones RT, French JJ, Scott J, Manas DM, Charnley RM. Radiofrequency ablation resulting in left lobe hypertrophy and improved resectability. Case Reports in Gastroenterology. 2011;5(1):132–135. [PMC free article: PMC3080585] [PubMed: 21512619]
  158. Stein A, Russel J, Peinert S, Arnold D. The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Therapeutic Advances in Medical Oncology. 2010;2(6):389–398. [PMC free article: PMC3126028] [PubMed: 21789150]
  159. Nikolic I, Pavin S, Kukic B, Bogdanovic B, Ilic M, Majdevac I, Petrovic T, Ivkovic-Kapicl T. Bevacizumab in neoadjuvant treatment of patients with liver metastases from colorectal carcinoma. Archive of Oncology. 2010;18(3):75–78.
  160. Reddy SK, Clary BM. A new era in defining indications for resectability of colorectal cancer liver metastases. Current Colorectal Cancer Reports. 2010;6(2):89–96.
  161. Sereno Moyano M, Casado Saenz E, De Castro-Carpeno J, Belda-Iniesta C. The combination of FOLFOX4 and bevacizumab may enable salvage surgery of unresectable liver metastases in colon cancer. Anti-Cancer Drugs. 2009;20(SPEC. ISS. 1):S4–S6. [PubMed: 19352109]
  162. Gold JS, DeMatteo RP. Combined surgical and molecular therapy: The gastrointestinal stromal tumor model. Annals of Surgery. 2006;244(2):176–184. [PMC free article: PMC1602162] [PubMed: 16858179]
  163. Fioole B, Jansen MC, van Duijnhoven FH, van Hillegersberg R, van Gulik TM, Borel Rinkes IHM. Combining partial liver resection and local ablation of liver tumours: A preliminary Dutch experience. World J Surg Oncol. 2006;4:46. [PMC free article: PMC1553444] [PubMed: 16846515]
  164. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. International Journal of Radiation Oncology Biology Physics. 2004;59(2):445–453. [PubMed: 15145161]
  165. Takamura A, Saito H, Kamada T, Hiramatsu K, Takeuchi S, Hasegawa M, Miyamoto N. Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. International Journal of Radiation Oncology Biology Physics. 2003;57(5):1357–1365. [PubMed: 14630274]
  166. Rutkowski P, Nowecki ZI, Nowak-Dement A, Nasierowska-Guttmejer A, Tuziak T, Pawel Nyckowski PR, Grzesiakowska U, Tacikowska M, Zurawski Z, Dziewirski W, Salamacha M, Krawczyk M, Ruya W, Kopacz A. Gastrointestinal stromal tumors - Clinical and morphological features. Polski Przeglad Chirurgiczny. 2003;75(4):374–384.
  167. Seymour K, Charnley RM, Rose JDG, Baudouin CJ, Manas D. Preoperative portal vein embolisation for primary and metastatic liver tumours: Volume effects, efficacy, complications and short-term outcome. HPB. 2002;4(1):21–26. [PMC free article: PMC2023908] [PubMed: 18333148]
  168. Economopoulos P, Christopoulos C. Glucagonoma. Annals of Gastroenterology. 2001;14(2):99–108.
  169. Van Ruth S, Mutsaerts E, Zoetmulder FAN, Van Coevorden F. Metastasectomy for liver metastases of non-colorectal primaries. European Journal of Surgical Oncology. 2001;27(7):662–667. [PubMed: 11669595]
  170. Chao C, Goldberg M, Hoffman JP. Surgical salvage therapy: Abdominoperineal resection for recurrent anal carcinoma, metastasectomy of recurrent colorectal cancer, and esophagectomy after combined chemoradiation. Current Opinion in Oncology. 2000;12(4):353–356. [PubMed: 10888421]

Level 2, Form Abstract Screening, Exclude if the answer to any of these... -> EXCLUDE

  1. Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell’Italia Meridionale Multicenter phase II study. Oncology. 2010;79(5–6):415–22. [PubMed: 21474966]
  2. Krieger PM, Tamandl D, Herberger B, Faybik P, Fleischmann E, Maresch J, Gruenberger T. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann Surg Oncol. 2011;18(6):1644–50. [PubMed: 21207168]
  3. Cui Y, Li H, Wu Q, Zhang T, Kong D, Song T, Ru T, Chen P, Li Q. Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities. J Gastrointest Surg. 2011;15(2):285–93. [PubMed: 20922574]
  4. Homayounfar K, Liersch T, Niessner M, Meller J, Lorf T, Becker H, Ghadimi BM. Multimodal treatment options for bilobar colorectal liver metastases. Langenbecks Arch Surg. 2010;395(6):633–41. [PMC free article: PMC2908753] [PubMed: 20213463]
  5. Wicherts DA, de Haas RJ, Andreani P, Sotirov D, Salloum C, Castaing D, Adam R, Azoulay D. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg. 2010;97(2):240–50. [PubMed: 20087967]
  6. Zhao R, Zhu J, Ji X, Cai J, Wan F, Li Q, Zhong B, Tucker S, Wang D. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. Jpn J Clin Oncol. 2010;40(1):10–6. [PubMed: 19773270]
  7. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–35. [PubMed: 19273699]
  8. Tse AN, Wu N, Patel D, Haviland D, Kemeny N. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol. 2009;64(5):935–44. [PubMed: 19221752]
  9. Lenz HJ. First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. Cancer Treat Rev. 2008;34(Suppl 2):S3–7. [PubMed: 19101405]
  10. Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, Hendlisz A. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53(22):6591–603. [PubMed: 18978442]
  11. Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, Wong L, Ward JH, Abbruzzese JL, Blanke CD. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009;27(5):469–75. [PMC free article: PMC3024913] [PubMed: 18941712]
  12. Ogata Y, Uchida S, Hisaka T, Horiuchi H, Mori S, Ishibashi N, Akagi Y, Shirouzu K. Intraoperative thermal ablation therapy for small colorectal metastases to the liver. Hepatogastroenterology. 2008;55(82–83):550–6. [PubMed: 18613406]
  13. Duffy A, Shia J, Huitzil-Melendez FD, Fong Y, O’Reilly EM. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma. Clin Colorectal Cancer. 2008;7(2):140–3. [PubMed: 18501074]
  14. Sugimoto M, Yasuda H, Koda K, Yamazaki M, Tezuka T, Takenoue T, Kosugi C, Higuchi R, Yamamoto S, Watayo Y, Yagawa Y, Suzuki M. Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. Hepatogastroenterology. 2007;54(78):1684–8. [PubMed: 18019695]
  15. Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, Matsuhashi N, Sakashita F, Nonaka K. Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol. 2007;95(6):491–8. [PubMed: 17219394]
  16. Szyszko T, Al-Nahhas A, Canelo R, Habib N, Jiao L, Wasan H, Pagou M, Tait P. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28(1):15–20. [PubMed: 17159544]
  17. Simon CJ, Dupuy DE, Iannitti DA, Lu DS, Yu NC, Aswad BI, Busuttil RW, Lassman C. Intraoperative triple antenna hepatic microwave ablation. AJR Am J Roentgenol. 2006;187(4):W333–40. [PubMed: 16985103]
  18. Leonard GD, Kemeny NE. Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. Dis Colon Rectum. 2006;49(3):407–10. [PubMed: 16475032]
  19. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9. [PubMed: 16230673]
  20. Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92(9):1155–60. [PubMed: 16035135]
  21. Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45(11):1892–7. [PubMed: 15534060]
  22. Machiavelli MR, Salum G, Perez JE, Ortiz EH, Romero AO, Bologna F, Vallejo CT, Lacava JA, Dominguez ME, Leone BA. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. Am J Clin Oncol. 2004;27(2):149–54. [PubMed: 15057154]
  23. Al-Sanea N, Isbister WH. Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control? ANZ J Surg. 2004;74(4):229–32. [PubMed: 15043733]
  24. Stella M, Percivale A, Pasqualini M, Profeti A, Gandolfo N, Serafini G, Pellicci R. Radiofrequency-assisted liver resection. J Gastrointest Surg. 2003;7(6):797–801. [PubMed: 13129559]
  25. King J, Zhao J, Clingan P, Morris D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res. 2003;23(1B):639–45. [PubMed: 12680160]
  26. Cerretani D, Roviello F, Pieraccini M, Civeli L, Correale P, Francini G, Marrelli D, De Manzoni G, Pinto E, Giorgi G. Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases. Vascul Pharmacol. 2002;39(1–2):1–6. [PubMed: 12616984]
  27. Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, Ruers TJ. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 2002;20(22):4453–8. [PubMed: 12431968]
  28. Stippel DL, Bohm S, Beckurts KT, Brochhagen HG, Holscher AH. Intraoperative radiofrequency ablation using a 3D navigation tool for treatment of colorectal liver metastases. Onkologie. 2002;25(4):346–50. [PubMed: 12232486]
  29. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002;29(6):815–20. [PubMed: 12029557]
  30. Wein A, Riedel C, Kockerling F, Martus P, Baum U, Brueckl WM, Reck T, Ott R, Hansler J, Bernatik T, Becker D, Schneider T, Hohenberger W, Hahn EG. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol. 2001;12(12):1721–7. [PubMed: 11843250]
  31. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O’Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88(10):1352–6. [PubMed: 11578291]
  32. Ruers TJ, Joosten J, Jager GJ, Wobbes T. Long-term results of treating hepatic colorectal metastases with cryosurgery. Br J Surg. 2001;88(6):844–9. [PubMed: 11412256]
  33. Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Coppola F, Van Kooten M, Rodger J, Giglio R, Balbiani L, Perazzo F, Montiel M, Chacon M, Pujol F, Mickiewicz E, Cazap E, Recondo G, Lastiri F, Simon J, Wasserman E, Schmilovich A. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer. 2001;37(8):1006–13. [PubMed: 11334726]
  34. Guadagni S, Pizzutilli A, Mancini E, Varrone A, Palumbo G, Amicucci G, Perri S, Deraco M, Fiorentini G. Significance of duplex/colour Doppler sonography in hepatic arterial chemotherapy for patients with liver metastases from colorectal carcinoma. Eur J Surg Oncol. 2000;26(4):381–6. [PubMed: 10873360]
  35. Hompes D, Prevoo W, Ruers T. Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer Imaging. 2011;11:23–30. [PMC free article: PMC3080126] [PubMed: 21435988]
  36. Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2011;35(3):684–92. [PubMed: 21181473]
  37. Kingham TP, D’Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010;102(8):988–95. [PubMed: 21166003]
  38. Guenette JP, Dupuy DE. Radiofrequency ablation of colorectal hepatic metastases. J Surg Oncol. 2010;102(8):978–87. [PubMed: 21166002]
  39. Rocha FG, D’Angelica M. Treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, and microwave coagulation. J Surg Oncol. 2010;102(8):968–74. [PubMed: 21166000]
  40. Garcia-Foncillas J, Diaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol. 2010;12(8):533–42. [PubMed: 20709651]
  41. Herman J, Messersmith W, Suh WW, Blackstock W, Cosman BC, Mohiuddin M, Poggi MM, Regine WF, Saltz L, Small W Jr, Zook J, Konski AA. ACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation. Curr Probl Cancer. 2010;34(3):201–10. [PubMed: 20541058]
  42. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg. 2010;145(4):340–5. discussion 345. [PubMed: 20404283]
  43. Deleporte A, Flamen P, Hendlisz A. State of the art: radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother. 2010;11(4):579–86. [PubMed: 20163269]
  44. Poulou LS, Ziakas PD, Xila V, Vakrinos G, Malagari K, Syrigos KN, Thanos L. Percutaneous radiofrequency ablation for unresectable colorectal liver metastases: time for shadows to disperse. Rev Recent Clin Trials. 2009;4(3):140–6. [PubMed: 20028323]
  45. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2009;(3):CD007823. [PubMed: 19588444]
  46. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, van Het Schip AD, Nijsen JF. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19(4):951–9. [PubMed: 18989675]
  47. Tachimori A, Yamada N, Amano R, Ohira M, Hirakawa K. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res. 2008;28(2A):629–38. [PubMed: 18507001]
  48. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2008;12(15):iii–ix. xi–162. [PubMed: 18462574]
  49. Koshariya M, Jagad RB, Kawamoto J, Papastratis P, Kefalourous H, Porfiris T, Tzouma C, Lygidakis NJ. An update and our experience with metastatic liver disease. Hepatogastroenterology. 2007;54(80):2232–9. [PubMed: 18265640]
  50. Shen P, Geisinger KR, Zagoria R, Levine EA. Pathologic correlation study of microwave coagulation therapy for hepatic malignancies using a three-ring probe. J Gastrointest Surg. 2007;11(5):603–11. [PubMed: 17393259]
  51. Yoo J, Lee YJ. Effect of hyperthermia on TRAIL-induced apoptotic death in human colon cancer cells: development of a novel strategy for regional therapy. J Cell Biochem. 2007;101(3):619–30. [PubMed: 17212362]
  52. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63. [PubMed: 15590187]
  53. Machi J, Oishi AJ, Mossing AJ, Furumoto NL, Oishi RH. Hand-assisted laparoscopic ultrasound-guided radiofrequency thermal ablation of liver tumors: a technical report. Surg Laparosc Endosc Percutan Tech. 2002;12(3):160–4. [PubMed: 12080255]
  54. Litvak DA, Wood TF, Tsioulias GJ, Chung M, Chawla SP, Foshag LJ, Morton DL, Ramming KP, Bilchik AJ. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol. 2002;9(2):148–55. [PubMed: 11888871]
  55. Muralidharan V, Christophi C. Interstitial laser thermotherapy in the treatment of colorectal liver metastases. 2001;76(1):73–81. [PubMed: 11223830]
  56. Asseburg C, Frank M, Kohne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther. 2011;33(4):482–97. [PubMed: 21635994]
  57. Hompes D, Boot H, van Tinteren H, Verwaal V. Unresectable peritoneal carcinomatosis from colorectal cancer: A single center experience. J Surg Oncol. 2011;104(3):269–73. [PubMed: 21465492]
  58. Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 ((90)Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999–2009). Crit Rev Oncol Hematol. 2011 [PubMed: 21388824]
  59. Wasan H, Kennedy A, Coldwell D, Sangro B, Salem R. Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases. Am J Clin Oncol. 2011 [PubMed: 21278562]
  60. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A. Radioembolization in the Treatment of Unresectable Liver Tumors: Experience Across a Range of Primary Cancers. Am J Clin Oncol. 2010 [PubMed: 21127414]
  61. Adam R, Hoti E, Folprecht G, Benson AB. Accomplishments in 2008 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res. 2009;3(5 Supplement 2):S15–22. [PMC free article: PMC2791382] [PubMed: 20011559]
  62. Blasiak-Wal I, Hansen VN, Hawkins M. Individualising stereotactic liver radiotherapy for large tumour volumes using liver normal tissue complication probability (NTCP) estimation. Radiotherapy and Oncology. 2011;99:S181.
  63. Gouvas N, Vini L, Silyvridou A, Diamantidou E, Dervenis C, Xynos E. Multidisciplinary management of locally recurrent colorectal cancer. Radiotherapy and Oncology. 2011;99:S395.
  64. Jones R, Fenwick S, Poston G, Malik H. Non-expert decision making in the management of metastatic colorectal cancer. HPB. 2011;13:54–55.
  65. HPB; Abstracts of the 9th Congress of the European-African HPBA, E-AHPBA; 2011. [PMC free article: PMC3093639] [PubMed: 21457418]
  66. Amelie D, Patrick F, Alain H. State of the art: Radiolabeled microspheres treatment for liver malignancies. Expert Opinion on Pharmacotherapy. 2010;11(4):579–586. [PubMed: 20163269]
  67. Bacchetti S, Pasqual E, Crozzolo E, Pellarin A, Cagol PP. Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: A review of medical devices complications in 3172 patients. Medical Devices: Evidence and Research. 2009;2(1):31–40. [PMC free article: PMC3417858] [PubMed: 22915912]
  68. Nafidi O, Desy D, Letoumeau R, Cote J, Plasse M, Vandenbroucke F, Roy A, Dagenais M, Lapointe RW. Hypertrophy of the non-embolized liver after chemotherapy. HPB. 2009;11(2):103–107. [PMC free article: PMC2697873] [PubMed: 19590632]
  69. Yamagami T, Terayama K, Yoshimatsu R, Matsumoto T, Miura H, Nishimura T. Use of N-butyl cyanoacrylate in implantation of a port-catheter system for hepatic arterial infusion chemotherapy with the fixed-catheter-tip method: Is it necessary? American Journal of Roentgenology. 2008;191(5):1523–1529. [PubMed: 18941095]
  70. Paschos KA, Bird N. Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis. Hippokratia. 2008;12(3):132–138. [PMC free article: PMC2504407] [PubMed: 18923747]
  71. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? Journal of Clinical Oncology. 2007;25(35):5649–5654. [PubMed: 18065736]
  72. Khodjibekova M, Szyszko T, Khan S, Nijran K, Tait P, Al-Nahhas A. Selective internal radiation therapy with Yttrium-90 for unresectable liver tumours. Reviews on Recent Clinical Trials. 2007;2(3):212–216. [PubMed: 18474007]
  73. Seki H, Shiina M. Placement of a long tapered side-hole catheter in the hepatic artery: Technical advantages, catheter stability, and arterial patency. American Journal of Roentgenology. 2006;187(5):1312–1320. [PubMed: 17056922]
  74. Kemeny NE. Current approaches for liver-only metastases in colorectal cancer. Community Oncology. 2006;3(6 SUPPL 2):26–35.
  75. Biasco G, Derenzini E, Fanello S, Brandi G. Liver metastases from colorectal cancer. European Journal of Oncology. 2005;10(1):45–54.
  76. Hanna NN. Radiofrequency ablation of primary and metastatic hepatic malignancies. Clinical Colorectal Cancer. 2004;4(2):92–100. [PubMed: 15285816]
  77. Kemeny N. Treatment of liver metastases with hepatic arterial infusion. European Surgery - Acta Chirurgica Austriaca. 2002;34(1):40–41.
  78. Fiorentini G, Poddie DB, De Giorgi U, Guglielminetti D, Giovanis P, Leoni M, Latino W, Dazzi C, Cariello A, Turci D, Marangolo M. Global approach to hepatic metastases from colorectal cancer: Indication and outcome of intra-arterial chemotherapy and other hepatic-directed treatments. Medical Oncology. 2000;17(3):163–173. [PubMed: 10962525]
  79. Abbasi SY, Taani HE, Saad A, Badheeb A, Addasi A. Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes. Gastrointest Cancer Res. 2011;4(4):122–7. [PMC free article: PMC3283110] [PubMed: 22368735]
  80. Abdelmaksoud MHK, Louie JD, Hwang GL, Kothary N, Minor DR, Sze DY. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. Journal of Vascular and Interventional Radiology. 2012;23(3):323–330. [PubMed: 22277275]
  81. Benson Iii AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW Jr, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett C. Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2011;9(11):1238–1289. [PubMed: 22056656]
  82. Borad MJ, Sigal D, Uronis H, Stephenson J, Bahary N, Rarick MU, DeMarco LC, Finnegan TJ, Chiorean EG, Ryan DP, Cohn AL, Ulrich BK, Harish VC, Anderes EN, Ma WW, Yu PP, Sinicrope F, Eng C, Sunkara UK, Reddy SG. Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. Journal of Clinical Oncology. 2011;29(15)
  83. Brown RE, Gibler KM, Metzger T, Trofimov I, Krebs H, Romero FD, Scoggins CR, McMasters KM, Martin Ii RCG. Imaged guided transarterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for hepatic metastases from melanoma: Early outcomes from a multi-institutional registry. American Surgeon. 2011;77(1):93–98. [PubMed: 21396314]
  84. Bruix J, Izzo F, Crocetti L, Vilgrain V, Abdel-Rehim M, Bianchi L, Ricke J, Pech M, Lencioni R. Irreversible electroporation for the treatment of early-stage hepatocellular carcinoma. A prospective multicenter Phase 2 study assessing safety and efficacy. Journal of Hepatology. 2012;56:S554.
  85. Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011;117(13):3053–9. [PubMed: 21264826]
  86. Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V, Llanos M, Garcia-Carbonero R, Abad A, Sevilla I, Duran I. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish neuroendocrine tumor group (GETNE0801). Neuroendocrinology. 2011;94:19–20.
  87. Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38(2):302–11. [PubMed: 21052661]
  88. Czito BG, Willett C, Kennedy-Newton P, Tyler DS, Hurwitz H, Uronis HE. A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC). Journal of Clinical Oncology. 2011;29(4)
  89. Czymek R, Dinter D, Loffler S, Gebhard M, Laubert T, Lubienski A, Bruch HP, Schmidt A. Electrochemical treatment: An investigation of dose-response relationships using an isolated liver perfusion model. Saudi J Gastroenterol. 2011;17(5):335–42. [PMC free article: PMC3178922] [PubMed: 21912061]
  90. Dahele M, Senan S. The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat. 2011;43(2):75–82. [PMC free article: PMC3138920] [PubMed: 21811422]
  91. Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: A long-term follow-up in 123 patients. Medical Oncology. 2011;28(SUPPL 1):S286–S290. [PubMed: 21107755]
  92. Edwards A, Ray CE. Transarterial therapies for unresectable cholangiocarcinoma: A meta-analysis. Journal of Vascular and Interventional Radiology. 2012;23(3):S101.
  93. Ercolani G, Cucchetti A, Cescon M, Peri E, Brandi G, Del Gaudio M, Ravaioli M, Zanello M, Pinna AD. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. Eur J Cancer. 2011;47(15):2291–8. [PubMed: 21652204]
  94. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, Lorusso PM. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131(3):933–7. [PMC free article: PMC3839045] [PubMed: 22083229]
  95. Grundmann RT. Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg. 2011;3(12):183–96. [PMC free article: PMC3251742] [PubMed: 22224173]
  96. Gueorguiev AL, Mackey R, Kowdley GC, Esquivel J, Cunningham SC. Minimally invasive evaluation and treatment of colorectal liver metastases. Int J Surg Oncol. 2011;2011:686030. [PMC free article: PMC3263653] [PubMed: 22312518]
  97. Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P, Buchler MW, Debus J, Combs SE. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiation Oncology. 2012;7(1) [PMC free article: PMC3338091] [PubMed: 22385572]
  98. Han D, Beasley GM, Tyler DS, Zager JS. Minimally invasive intra-arterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion. Expert Opinion on Drug Metabolism and Toxicology. 2011;7(11):1383–1394. [PMC free article: PMC4630979] [PubMed: 21978383]
  99. Haug AR, Donfack BPT, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. Journal of Nuclear Medicine. 2012;53(3):371–377. [PubMed: 22331219]
  100. Hery G, Franchi-Abella S, Habes D, Brugieres L, Martelli H, Fabre M, Pariente D, Gauthier F, Jacquemin E, Branchereau S. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy. Pediatric Blood and Cancer. 2011;57(7):1270–1275. [PubMed: 21910210]
  101. Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, Rauch B, Trumm CT, Jakobs TF, Helmberger TK, Reiser MF, Kolligs FT. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival. CardioVascular and Interventional Radiology. 2012;35(1):105–116. [PubMed: 21431970]
  102. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011;68(6):1595–602. [PMC free article: PMC3519425] [PubMed: 21556747]
  103. Iwase H, Shimada M, Tsuzuki T, Ina K, Sugihara M, Haruta J, Shinoda M, Kumada T, Goto H. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. Oncology. 2011;80(1–2):76–83. [PubMed: 21659786]
  104. John BJ, Davidson BR. Treatment options for unresectable neuroendocrine liver metastases. Expert Review of Gastroenterology and Hepatology. 2012;6(3):357–369. [PubMed: 22646257]
  105. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, Kondo Y, Taniguchi M, Tagawa K, Ikeda M, Morizane C, Okusaka T, Arioka H, Shiina S, Omata M. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;67(2):315–24. [PubMed: 20390419]
  106. Khajanchee YS, Hammill CW, Cassera MA, Wolf RF, Hansen PD. Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis. Arch Surg. 2011;146(12):1416–23. [PubMed: 22288086]
  107. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, Olthoff K, Christians K, Pappas S, Rilling W, Soulen MC. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498–505. [PubMed: 21425151]
  108. Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30(1):387–94. [PMC free article: PMC3896232] [PubMed: 20839030]
  109. Kim JW, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. International Journal of Radiation Oncology Biology Physics. 2012;82(3):1172–1178. [PubMed: 21570203]
  110. Kolosov IV, Ishchenko RV. [The results of palliative locoregional chemotherapy of primary and metastatic hepatic cancer]. Klin Khir. 2011;(9):31–3. [PubMed: 22168021]
  111. Kratochwil C, Lopez-Benitez R, Mier W, Haufe S, Isermann B, Kauczor HU, Choyke PL, Haberkorn U, Giesel FL. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18(5):595–602. [PMC free article: PMC8369516] [PubMed: 21791571]
  112. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47(14):2117–27. [PubMed: 21664811]
  113. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43. [PubMed: 22261548]
  114. Lacin S, Oz I, Ozkan E, Kucuk O, Bilgic S. Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response. Cancer Biother Radiopharm. 2011;26(5):631–7. [PubMed: 21950557]
  115. Lam VWT, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HCC, Richardson AJ. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Annals of Surgical Oncology. 2012;19(4):1292–1301. [PubMed: 21922338]
  116. Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(12):1697–705. [PubMed: 21983055]
  117. Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81(SUPPL 1):123–133. [PubMed: 22212946]
  118. Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver. 2012;6(2):139–48. [PMC free article: PMC3343153] [PubMed: 22570744]
  119. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg. 2012;255(2):237–47. [PubMed: 22041509]
  120. Lenoir L, Pracht M, Rolland Y, Edeline J, Laffont S, Ardisson V, Mesbah H, Poree P, Raoul JL, Boucher E, Garin E. Yttrium-90 microspheres radioembolization in hepatocellular carcinoma with portal vein thrombosis: Results on 40 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging. 2011;38:S95.
  121. Lim HY, Lee J, Chang H, Kim JS, Choi HJ, Lee MA, Jang J, Jeung H, Kang JH, Lee HW, Shin D, Jang HJ, Sun J, Park SH, Park JO, Park Y, Kang WK. Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma. Journal of Clinical Oncology. 2011;29(18)
  122. Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. Oncologist. 2012 [PMC free article: PMC3399654] [PubMed: 22673633]
  123. Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413–20. [PubMed: 20839057]
  124. Maire F, Lombard-Bohas C, O’Toole D, Vullierme MP, Ruszniewski P. Hepatic arterial embolization versus chemoembolization in patients with liver metastases of digestive neuroendocrine tumors. Neuroendocrinology. 2011;94:34–35.
  125. Martin RC, Robbins K, Fages JF, Romero FD, Rustein L, Tomalty D, Monaco R. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat. 2012;132(2):753–63. [PubMed: 22200868]
  126. Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Gates VL, Atassi B, Newman S, Omary RA, Benson ABR, Salem R. Radioembolization for Neuroendocrine Liver Metastases: Safety, Imaging, and Long-Term Outcomes. Int J Radiat Oncol Biol Phys. 2012;83(3):887–894. [PMC free article: PMC3297703] [PubMed: 22137020]
  127. Merle P, Abergel A, Masliah C, Rosmorduc O, Bronowicki JP, Pageaux GP, Zarski JPH, Degos F, Dorval E, Pelletier G, Verset G, Attali P. A randomized phase ii trial of doxorubicintransdrug (trademark) (livatag(registered trademark)) demonstrates significant overall survival increase in inoperable hepatocellular carcinoma (hcc) patients. Hepatology. 2011;54:1388A–1389A.
  128. Mir O, Domont J, Cioffi A, Bonvalot S, Boulet B, Le Pechoux C, Terrier P, Spielmann M, Le Cesne A. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. European Journal of Cancer. 2011;47(4):515–519. [PubMed: 21251814]
  129. Moehler M, Kanzler S, Schimanski CC, Worns MA, Denzer U, Kolligs F, Ebert M, Distelrath A, Zeuzem S, Lammert F, Geissler M, Lohse A, Dollinger M, Lindig U, Durr M, Lubomierski N, Kabisch M, Schadmand-Fischer S, Galle PR. A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naive advanced or metastatic biliary tract cancer: First safety and efficacy data. Onkologie. 2011;34:217.
  130. Okabe K, Beppu T, Masuda T, Hayashi H, Okabe H, Komori H, Horino K, Sugiyama SI, Ishiko T, Takamori H, Yamanaka T, Baba H. Portal vein embolization can prevent intrahepatic metastases to non-embolized liver. Hepato-Gastroenterology. 2012;59(114):538–541. [PubMed: 22353520]
  131. Osaka Y, Shinohara M, Hoshino S, Ogata T, Takagi Y, Tsuchida A, Aoki T. Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res. 2011;31(2):633–8. [PubMed: 21378349]
  132. Pagliaro LC, Munsell M, Harris D, Carolla RL, Siefker-Radtke AO. Gemcitabine, paclitaxel, and doxorubicin for patients (pts) with urothelial carcinoma (UC) and renal insufficiency: Preliminary results of a multicenter phase II study. Journal of Clinical Oncology. 2011;29(7)
  133. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17(7):1973–83. [PubMed: 21349999]
  134. Picozzi VJ, Nguyen M, Traverso LW, Kozarek RA. The virginia mason pancreatic cancer database. Journal of Clinical Oncology. 2011;29(4)
  135. Pracht M, Edeline J, Lenoir L, La Tournerie M, Garin E, Rolland Y, Raoul J, Boucher E. Hepatocellular carcinoma with portal vein thrombosis treated with yttrium-90 microsphere radioembolization results on 22 consecutive patients. Journal of Clinical Oncology. 2011;29(15)
  136. Quan D, Gallinger S, Nhan C, Auer RA, Biagi JJ, Fletcher GG, Law CH, Moulton CA, Ruo L, Wei AC, McLeod RS. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review. Surgery. 2012;151(6):860–70. [PubMed: 22316439]
  137. Rajekar H, Bogammana K, Stubbs RS. Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: A new and effective modality for treatment. International Journal of Hepatology. 2011 [PMC free article: PMC3227504] [PubMed: 22164335]
  138. Ruers T. Colorectal cancer with synchronous liver metastases. European Journal of Cancer. 2012;48:S2.
  139. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(11):1545–52. [PubMed: 21849247]
  140. Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Koeberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology. 2011;81(1):50–4. [PubMed: 21921646]
  141. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther. 2011;7(4):463–75. [PubMed: 22269411]
  142. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma- A meta-analysis. Hepatology. 2011;54:1395A. [PubMed: 22269411]
  143. Schmid I, Haberle B, Albert MH, Corbacioglu S, Frohlich B, Graf N, Kammer B, Kontny U, Leuschner I, Scheel-Walter HG, Scheurlen W, Werner S, Wiesel T, von Schweinitz D. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer. 2012;58(4):539–44. [PubMed: 21922643]
  144. Seinstra BA, Defreyne L, Lambert B, Lam M, Verkooijen L, Van Erpecum KJ, Van Hoek B, Van Erkel AR, Coenraad MJ, Al Younis I, Van Vlierberghe H, Van Den Bosch M. Transarterial RAdioembolization versus ChemoEmbolization for the treatment of HCC: TRACE trial-an international multicenter randomized controlled trial. Journal of Vascular and Interventional Radiology. 2012;23(3):S150–S151.
  145. Seront E, Van den Eynde M. Liver-Directed Therapies: Does It Make Sense in the Current Therapeutic Strategy for Patients With Confined Liver Colorectal Metastases? Clin Colorectal Cancer. 2012 [PubMed: 22306027]
  146. Shim CS. Photodynamic therapy for hilar cholangiocarcinoma. Photodiagnosis and Photodynamic Therapy. 2011;8(2):218–219.
  147. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O’Dwyer PJ, Shaked A, Reddy R, Olthoff K. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer. 2011;117(14):3187–92. [PubMed: 21264839]
  148. Teunissen JJM, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(SUPPL 1):S27–S51. [PubMed: 22005114]
  149. Thakur A, Littrup P, Paul EN, Adam B, Heilbrun LK, Lum LG. Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother. 2011;34(5):457–67. [PMC free article: PMC3893916] [PubMed: 21577139]
  150. Tomkovich KR. Ablation of breast cancer. CardioVascular and Interventional Radiology. 2011;34:415–416.
  151. Vogl TJ, Naguib NNN, Lehnert T, Nour-Eldin NEA, Eichler K, Zangos S, Gruber-Rouh T. Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: Indications, outcomes and role in patient’s management. Gynecologic Oncology. 2012;124(2):225–229. [PubMed: 22079359]
  152. Whitney R, Valek V, Fages JF, Garcia A, Narayanan G, Tatum C, Hahl M, Martin RC 2nd. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist. 2011;16(5):594–601. [PMC free article: PMC3228197] [PubMed: 21508068]
  153. Wieners G, Mohnike K, Peters N, Bischoff J, Kleine-Tebbe A, Seidensticker R, Seidensticker M, Gademann G, Wust P, Pech M, Ricke J. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study. Radiother Oncol. 2011;100(2):314–9. [PubMed: 21497930]
  154. Wu YV, Tomaszewski G, Groman A, Iyer R, Kuvshinoff B. Comparison of yttrium-90 microspheres (Y-90) and transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS). Annals of Surgical Oncology. 2012;19:S32.
  155. Yarra P, Rodriguez A. A rare etiology of brain metastasis: Squamous cell carcinoma of the esophagus. American Journal of Gastroenterology. 2011;106:S187.
  156. Yi JH, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY, Kang WK. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer. 2012;106(9):1469–74. [PMC free article: PMC3341944] [PubMed: 22460270]
  157. Yu J, Meng X, Wang JH, Sun X, Wang L, Ye M, Feng PB, Zhu GY, Lu Y, Zhu SC. KRAS mutation status and toxicity of cetuximab, paclitaxel, cisplatin, and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study. Journal of Clinical Oncology. 2011;29(15)
  158. Zager J, Nutting C. Chemosaturation therapy with percutaneous hepatic perfusions of melphalan versus standard of care in patients with hepatic metastases from melanoma: A randomized multicenter phase 3 study. Journal of Vascular and Interventional Radiology. 2012;23(3):S3.
  159. Zhou Y, Huang J, Yang L, Cai GR, Xu HB, Wang WJ, Shi KY, Sun Y. Phase II trial of paclitaxel and cisplatin combination given biweekly as first-line chemotherapy in patients with advanced or metastatic squamous cell carcinoma of esophagus from a single center in China. Journal of Clinical Oncology. 2011;29(15)

Level 3, Form CRC Full-textScreening, trtment Exclude

  1. van Iersel LB, Koopman M, van de Velde CJ, Mol L, van Persijn van Meerten EL, Hartgrink HH, Kuppen PJ, Vahrmeijer AL, Nortier JW, Tollenaar RA, Punt C, Gelderblom H. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol. 2010;21(8):1662–7. [PubMed: 20110289]
  2. Pilati P, Mammano E, Mocellin S, Tessari E, Lise M, Nitti D. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy. Anticancer Res. 2009;29(10):4139–44. [PubMed: 19846962]
  3. Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009;16(7):1852–9. [PMC free article: PMC8381241] [PubMed: 19434456]
  4. Lao OB, Farjah F, Flum DR, Yeung RS. Adverse events after radiofrequency ablation of unresectable liver tumors: a single-center experience. Am J Surg. 2009;198(1):76–82. [PubMed: 19285299]
  5. Puls R, Langner S, Rosenberg C, Hegenscheid K, Kuehn JP, Noeckler K, Hosten N. Laser ablation of liver metastases from colorectal cancer with MR thermometry: 5-year survival. J Vasc Interv Radiol. 2009;20(2):225–34. [PubMed: 19109037]
  6. Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology. 2009;250(1):281–9. [PubMed: 19092099]
  7. Howard JH, Tzeng CW, Smith JK, Eckhoff DE, Bynon JS, Wang T, Arnoletti JP, Heslin MJ. Radiofrequency ablation for unresectable tumors of the liver. Am Surg. 2008;74(7):594–600. discussion 600–1. [PubMed: 18646476]
  8. Ng SS, Yu SC, Lai PB, Lau WY. Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies. Dig Dis Sci. 2008;53(10):2813–7. [PubMed: 18320307]
  9. Seki H, Ozaki T, Shiina M. Side-hole catheter placement for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer: long-term treatment and survival benefit. AJR Am J Roentgenol. 2008;190(1):111–20. [PubMed: 18094301]
  10. Suppiah A, White TJ, Roy-Choudhury SH, Breen DJ, Cast J, Maraveyas A, Hartley JE, Monson JR. Long-term results of percutaneous radiofrequency ablation of unresectable colorectal hepatic metastases: final outcomes. Dig Surg. 2007;24(5):358–60. [PubMed: 17785980]
  11. Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porcheron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33(5):590–6. [PubMed: 17321714]
  12. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol. 2007;33(1):67–71. [PubMed: 17174059]
  13. Van Nieuwenhove Y, Aerts M, Neyns B, Delvaux G. Techniques for the placement of hepatic artery catheters for regional chemotherapy in unresectable liver metastases. Eur J Surg Oncol. 2007;33(3):336–40. [PubMed: 17084580]
  14. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30. [PubMed: 16982546]
  15. Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J. 2006;12(4):318–26. [PubMed: 16925977]
  16. Amersi FF, McElrath-Garza A, Ahmad A, Zogakis T, Allegra DP, Krasne R, Bilchik AJ. Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg. 2006;141(6):581–7. discussion 587–8. [PubMed: 16785359]
  17. Stella M, Mithieux F, Meeus P, Kaemmerlen P, Lafon C, Rivoire M. Transpleurodiaphragmatic cryosurgical ablation for recurrent unresectable colorectal liver metastases. J Surg Oncol. 2006;93(4):268–72. [PubMed: 16496368]
  18. Pacella CM, Valle D, Bizzarri G, Pacella S, Brunetti M, Maritati R, Osborn J, Stasi R. Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of a phase II study. Acta Oncol. 2006;45(1):77–83. [PubMed: 16464799]
  19. Yan TD, Padang R, Morris DL. Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases. J Am Coll Surg. 2006;202(1):100–11. [PubMed: 16377503]
  20. Ishibashi K, Yoshimatsu K, Yokomizo H, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Katsube T, Naritaka Y, Ogawa K. Low-dose leucovorin and 5-Fluorouracil for unresectable multiple liver metastasis from colorectal cancer. Anticancer Res. 2005;25(6C):4747–52. [PubMed: 16334171]
  21. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK, Knol J, Dawson LA, Pan C, Lawrence TS. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23(34):8739–47. [PubMed: 16314634]
  22. Nag S, DeHaan M, Scruggs G, Mayr N, Martin EW. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64(3):736–44. [PubMed: 16274935]
  23. Joosten J, Jager G, Oyen W, Wobbes T, Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol. 2005;31(10):1152–9. [PubMed: 16126363]
  24. Kemeny N, Eid A, Stockman J, Gonen M, Schwartz L, Tetzlaff E, Paty P. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol. 2005;91(2):97–101. [PubMed: 16028279]
  25. Qin B, Kato K, Mitsugi K, Nakamura M, Tanaka R, Baba E, Ariyama H, Kuroiwa T, Harada M, Nakano S. Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2006;57(1):114–9. [PubMed: 16001177]
  26. Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L, Espat J, Stojadinovic A, Cohen AM, Fong Y, Paty PB. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57–65. [PubMed: 15978444]
  27. You YT, Changchien CR, Huang JS, Ng KK. Combining systemic chemotherapy with chemoembolization in the treatment of unresectable hepatic metastases from colorectal cancer. Int J Colorectal Dis. 2006;21(1):33–7. [PubMed: 15942741]
  28. Navarra G, Ayav A, Weber JC, Jensen SL, Smadga C, Nicholls JP, Habib NA, Jiao LR. Short- and-long term results of intraoperative radiofrequency ablation of liver metastases. Int J Colorectal Dis. 2005;20(6):521–8. [PubMed: 15864606]
  29. Yamagami T, Kato T, Tanaka O, Hirota T, Nishimura T. Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2005;16(4):549–54. [PubMed: 15802457]
  30. Christophi C, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy. World J Surg. 2004;28(10):987–94. [PubMed: 15573253]
  31. Pohlen U, Mansmann U, Berger G, Germer CT, Gallkowski U, Boese-Landgraf J, Buhr HJ. Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. Anticancer Res. 2004;24(5B):3275–82. [PubMed: 15510623]
  32. Kerkar S, Carlin AM, Sohn RL, Steffes C, Tyburski J, Littrup P, Weaver D. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors. Surgery. 2004;136(4):770–9. [PubMed: 15467661]
  33. White TJ, Roy-Choudhury SH, Breen DJ, Cast J, Maraveyas A, Smyth EF, Hartley JE, Monson JR. Percutaneous radiofrequency ablation of colorectal hepatic metastases - initial experience. An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. Dig Surg. 2004;21(4):314–20. [PubMed: 15365230]
  34. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25. discussion 825–7. [PMC free article: PMC1356290] [PubMed: 15166961]
  35. Venturini M, Angeli E, Salvioni M, De Cobelli F, Ronzoni M, Aldrighetti L, Stella M, Carlucci M, Staudacher C, Di Carlo V, Ferla G, Villa E, Del Maschio A. Complications after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical relevance and management in 204 patients. AJR Am J Roentgenol. 2004;182(6):1417–26. [PubMed: 15149985]
  36. Muller H, Nakchbandi V, Chatzisavvidis I, von Voigt C. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology. 2003;50(54):1919–26. [PubMed: 14696433]
  37. Rothbarth J, Pijl ME, Vahrmeijer AL, Hartgrink HH, Tijl FG, Kuppen PJ, Tollenaar RA, van de Velde CJ. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg. 2003;90(11):1391–7. [PubMed: 14598420]
  38. Hamada A, Yamakado K, Nakatsuka A, Tanaka N, Takeda K. Repeated hepatic arterial infusion chemotherapy using an implanted port system in patients with unresectable malignant liver neoplasms: significant factors affecting early hepatic arterial occlusion. Oncol Rep. 2003;10(6):1821–7. [PubMed: 14534703]
  39. Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, Woitaschek D, Zangos S. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology. 2003;229(2):457–64. [PubMed: 14500854]
  40. Mancuso A, Giuliani R, Accettura C, Palma M, D’Auria G, Cecere F, Paoluzzi L, Bezzi M, Massidda B, Cortesi E. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res. 2003;23(2C):1917–22. [PubMed: 12820479]
  41. Fallik D, Ychou M, Jacob J, Colin P, Seitz JF, Baulieux J, Adenis A, Douillard JY, Couzigou P, Mahjoubi R, Ducreux M, Mahjoubi M, Rougier P. Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. Ann Oncol. 2003;14(6):856–63. [PubMed: 12796022]
  42. Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol. 2003;10(1):52–8. [PubMed: 12513961]
  43. Miyanari N, Mori T, Takahashi K, Yasuno M. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum. 2002;45(11):1503–9. [PubMed: 12432299]
  44. Bloomston M, Binitie O, Fraiji E, Murr M, Zervos E, Goldin S, Kudryk B, Zwiebel B, Black T, Fargher S, Rosemurgy AS. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002;68(9):827–31. [PubMed: 12356160]
  45. Alexander HR Jr, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, Beresnev T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer. 2002;95(4):730–6. [PubMed: 12209715]
  46. Liu LX, Zhang WH, Jiang HC, Zhu AL, Wu LF, Qi SY, Piao DX. Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. World J Gastroenterol. 2002;8(4):663–7. [PMC free article: PMC4656317] [PubMed: 12174375]
  47. Popov I, Lavrnic S, Jelic S, Jezdic S, Jasovic A. Chemoembolization for liver metastases from colorectal carcinoma: risk or a benefit. Neoplasma. 2002;49(1):43–8. [PubMed: 12044059]
  48. Kosari K, Gomes M, Hunter D, Hess DJ, Greeno E, Sielaff TD. Local, intrahepatic, and systemic recurrence patterns after radiofrequency ablation of hepatic malignancies. J Gastrointest Surg. 2002;6(2):255–63. [PubMed: 11992812]
  49. Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, Furumoto NL, Oishi RH. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg. 2001;5(5):477–89. [PubMed: 11985998]
  50. Iannitti DA, Dupuy DE, Mayo-Smith WW, Murphy B. Hepatic radiofrequency ablation. Arch Surg. 2002;137(4):422–6. discussion 427. [PubMed: 11926946]
  51. Gruenberger T, Zhao J, King J, Chung T, Clingan PR, Morris DL. Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy. Cancer. 2002;94(6):1753–9. [PubMed: 11920538]
  52. Huang A, McCall JM, Weston MD, Mathur P, Quinn H, Henderson DC, Allen-Mersh TG. Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg. 2002;89(3):303–10. [PubMed: 11872054]
  53. Wong SL, Edwards MJ, Chao C, Simpson D, McMasters KM. Radiofrequency ablation for unresectable hepatic tumors. Am J Surg. 2001;182(6):552–7. [PubMed: 11839316]
  54. Kohnoe S, Endo K, Yamamoto M, Ikeda Y, Toh Y, Baba H, Tajima T, Okamura T. Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. Surgery. 2002;131(1 Suppl):S128–34. [PubMed: 11821799]
  55. Kimoto T, Yamanoi A, Uchida M, Makino Y, Ono T, Kohno H, Nagasue N. Repeated hepatic dearterialization for unresectable carcinomas of the liver: report of a 10-year experience. Surg Today. 2001;31(11):984–90. [PubMed: 11766086]
  56. Link KH, Sunelaitis E, Kornmann M, Schatz M, Gansauge F, Leder G, Formentini A, Staib L, Pillasch J, Beger HG. Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival. Cancer. 2001;92(11):2746–53. [PubMed: 11753947]
  57. Aldrighetti L, Arru M, Ronzoni M, Salvioni M, Villa E, Ferla G. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer. Hepatogastroenterology. 2001;48(41):1302–7. [PubMed: 11677951]
  58. Muller H, Nakchbandi W, Chatzissavvidis I, Valek V. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. Eur J Surg Oncol. 2001;27(7):652–61. [PubMed: 11669594]
  59. Lygidakis NJ, Sgourakis G, Dedemadi G, Safioleus MC, Nestoridis J. Regional chemoimmunotherapy for nonresectable metastatic liver disease of colorectal origin. A prospective randomized study. Hepatogastroenterology. 2001;48(40):1085–7. [PubMed: 11490806]
  60. Mack MG, Straub R, Eichler K, Engelmann K, Zangos S, Roggan A, Woitaschek D, Bottger M, Vogl TJ. Percutaneous MR imaging-guided laser-induced thermotherapy of hepatic metastases. Abdom Imaging. 2001;26(4):369–74. [PubMed: 11441548]
  61. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology. 2001;48(38):333–7. [PubMed: 11379303]
  62. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294–302. [PubMed: 11360053]
  63. Lorenz M, Mueller HH, Mattes E, Gassel HJ, Junginger T, Saeger HD, Schramm H, Staib-Sebler E, Vetter G, Heinrich S, Kohne CH. Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. Ann Oncol. 2001;12(3):321–5. [PubMed: 11332142]
  64. Copur MS, Capadano M, Lynch J, Goertzen T, McCowan T, Brand R, Tempero M. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access. J Clin Oncol. 2001;19(9):2404–12. [PubMed: 11331319]
  65. Lans TE, Bartlett DL, Libutti SK, Gnant MF, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. Clin Cancer Res. 2001;7(4):784–90. [PubMed: 11309322]
  66. Rivoire M, De Cian F, Meeus P, Gignoux B, Frering B, Kaemmerlen P. Cryosurgery as a means to improve surgical treatment of patients with multiple unresectable liver metastases. Anticancer Res. 2000;20(5C):3785–90. [PubMed: 11268455]
  67. Heslin MJ, Medina-Franco H, Parker M, Vickers SM, Aldrete J, Urist MM. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. Arch Surg. 2001;136(3):318–23. [PubMed: 11231853]
  68. van Riel JM, van Groeningen CJ, Albers SH, Cazemier M, Meijer S, Bleichrodt R, van den Berg FG, Pinedo HM, Giaccone G. Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. Ann Oncol. 2000;11(12):1563–70. [PubMed: 11205464]
  69. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129(2):176–87. [PubMed: 11174711]
  70. de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000;175(6):1619–25. [PubMed: 11090390]
  71. Seifert JK, Achenbach T, Heintz A, Bottger TC, Junginger T. Cryotherapy for liver metastases. Int J Colorectal Dis. 2000;15(3):161–6. [PubMed: 10954187]
  72. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, Lawrence TS. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18(11):2210–8. [PubMed: 10829040]
  73. Gillams AR, Lees WR. Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum. 2000;43(5):656–61. [PubMed: 10826427]
  74. Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2000;18(2):243–54. [PubMed: 10637236]
  75. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008;15(10):2757–64. [PubMed: 18618182]
  76. Fiorentini G, Poddie DB, Cantore M, Rossi S, Tumolo S, Dentico P, Bernardeschi P, Guadagni S, Rossi G, Valori VM, De Simone M. Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study. J Chemother. 2004;16 Suppl 5:51–4. [PubMed: 15675479]
  77. Mancini R, Tedesco M, Garufi C, Filippini A, Arcieri S, Caterino M, Pizzi G, Cortesi E, Spila A, Sperduti I, Cosimelli M. Hepatic arterial infusion (HAI) of cisplatin and systemic fluorouracil in the treatment of unresectable colorectal liver metastases. Anticancer Res. 2003;23(2C):1837–41. [PubMed: 12820466]
  78. Heinrich S, Petrowsky H, Schwinnen I, Staib-Sebler E, Gog C, El-Ganainy A, Gutt C, Muller HH, Lorenz M. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery. 2003;133(1):40–8. [PubMed: 12563236]
  79. Bilchik AJ, Wood TF, Chawla SP, Rose DM, Chung MH, Stern SS, Foshag LJ, Ramming KP. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. Clin Colorectal Cancer. 2001;1(1):36–42. [PubMed: 12445377]
  80. Ng KM, Chua TC, Saxena A, Zhao J, Chu F, Morris DL. Two Decades of Experience with Hepatic Cryotherapy for Advanced Colorectal Metastases. Ann Surg Oncol. 2011 [PubMed: 21913018]
  81. Hammill CW, Billingsley KG, Cassera MA, Wolf RF, Ujiki MB, Hansen PD. Outcome after laparoscopic radiofrequency ablation of technically resectable colorectal liver metastases. Annals of Surgical Oncology. 2011;18(7):1947–1954. [PubMed: 21399885]
  82. Vogl TJ, Jost A, Nour-Eldin NA, Mack MG, Zangos S, Naguib NN. Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma. Br J Cancer. 2012;106(7):1274–9. [PMC free article: PMC3314788] [PubMed: 22382689]

Level 3, Form CRC Full-textScreening, Not Relevant Design -> Exclude

  1. Iguchi T, Idani H, Asami S, Endo H, Inaba Y, Arai Y, Kanazawa S. Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients. Acta Med Okayama. 2011;65(1):49–53. [PubMed: 21339796]
  2. Tanida T, Ohue M, Noura S, Seki Y, Gotoh K, Motoori M, Kishi K, Yamada T, Miyashiro I, Ohigashi H, Yano M, Ishikawa O. Long-term complete response of unresectable liver metastases from colorectal cancer. Hepatogastroenterology. 2010;57(101):764–7. [PubMed: 21033225]
  3. Guiu B, Vincent J, Guiu S, Ladoire S, Ortega-Deballon P, Cercueil JP, Chauffert B, Ghiringhelli F. Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer. World J Gastroenterol. 2010;16(9):1150–4. [PMC free article: PMC2835794] [PubMed: 20205288]
  4. Viudez A, Rodriguez J, Gil-Bazo I. Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom? Cardiovasc Intervent Radiol. 2009;32(3):603–4. [PubMed: 19194743]
  5. Garrean S, Muhs A, Bui JT, Blend MJ, Owens C, Helton WS, Espat NJ. Complete eradication of hepatic metastasis from colorectal cancer by Yttrium-90 SIRT. World J Gastroenterol. 2007;13(21):3016–9. [PMC free article: PMC4171159] [PubMed: 17589957]
  6. Veenendaal LM, de Jager A, Stapper G, Borel Rinkes IH, van Hillegersberg R. Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed Laser Surg. 2006;24(1):3–9. [PubMed: 16503781]
  7. Milandri M, Calzolari F, Passardi A, Ridolfi R, Tison C, Giampalma E, Golfieri R, Ridolfi L, Mura G, Vagliasindi A, Fra Marini M, Verdecchia GM. Intra-arterial chemotherapy for liver metastases from colorectal cancer. Suppl Tumori. 2005;4(3):S45. [PubMed: 16437895]
  8. Shibata C, Jin XL, Funayama Y, Fukushima K, Takahashi K, Hashimoto A, Nagao M, Haneda S, Watanabe K, Matsuno S, Sasaki I, Naito H. Effect of intra-arterial cisplatin on multiple liver metastases from rectal cancer associated with ulcerative colitis. Tohoku J Exp Med. 2004;202(1):57–61. [PubMed: 14738325]
  9. Ogata Y, Tsuda H, Matono K, Kumabe T, Saitsu H, Hara H, Akagi Y, Araki Y, Sata M, Shirouzu K. Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case. Surg Today. 2003;33(6):448–53. [PubMed: 12768372]
  10. Savier E, Azoulay D, Huguet E, Lokiec F, Gil-Delgado M, Bismuth H. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. Arch Surg. 2003;138(3):325–32. [PubMed: 12611582]
  11. Sikma MA, Coenen JL, Kloosterziel C, Hasselt BA, Ruers TJ. A breakthrough in cryosurgery. Surg Endosc. 2002;16(5):870. [PubMed: 11997844]
  12. Jamdar S, Jegatheeswaran S, Bandara A, Sheen AJ, Siriwardena AK. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases (Br J Surg 2010; 97: 240–250). Br J Surg. 2010;97(6):958. author reply 958. [PubMed: 20474008]
  13. De Jong FA, Mathijssen RH, Verweij J. Limited potential of hepatic arterial infusion of irinotecan. J Chemother. 2004;16 Suppl 5:48–50. [PubMed: 15675478]
  14. Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Amesur N, Avril N. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2005;32(6):723. [PubMed: 15599525]
  15. Seki A, Hori S. Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study. Int J Clin Oncol. 2011 [PubMed: 21249412]
  16. Castiglioni S, Tozzi A, Mancosu P, Navarria P, Pentimalli S, Alongi F, Clerici E, Fogliata A, Cozzi L, Torzilli G, Scorsetti M. Sbrt dose escalation phase i study for liver metastases using volumetric modulated arc therapy. Radiotherapy and Oncology. 2011;99:S354.
  17. Barsukov YA, Aliev VA, Tkachev SI, Tyulyandin SA, Fedyanin MY, Kuzmichev DV, Mammadli ZZ, Atroshenko AO. Our experience in treatment rectal cancer patients with synchronous metastases. European Surgery - Acta Chirurgica Austriaca. 2011;43:16.
  18. Barsukov YA, Aliev VA, Tkachev SI, Tjulandin SA, Fedjanin MY, Kuzmichev DV, Mamedli ZZ, Atroshchenko AO. Our experience in treating patients with synchronous distant metastases of rectal cancer. European Surgery - Acta Chirurgica Austriaca. 2011;43:17.
  19. Bhardwaj NB, Ngu W, Strickland A, Elabassy M, Loyd DL. Microwave ablation for unresectable hepatic tumours: Long term clinical results. HPB. 2011;13:73–74.
  20. Evrard S, Rivoire M, Arnaud JP, Ayav A, Cuhna AS, Regimbeau JM, Mathoulin S, Bellera C. Intraoperative radiofrequency ablation combined or not with resection to treat unresectable colorectal metastases. Results of the multicentric phase 2 study: ARF2003. HPB. 2011;13:1.
  21. Manchon Walsh P, Borras JM, Ferro T, Espinas JA. Colorectal cancer OncoGuia. Clinical and Translational Oncology. 2010;12(3):188–210. [PubMed: 20231124]
  22. Vlad L. Hepatic intraarterial chemotherapy - A therapeutic alternative in unresectable liver tumours. Romanian Journal of Gastroenterology. 2000;9(3):193–200.
  23. Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol. 2012;18(10):1003–8. [PMC free article: PMC3296972] [PubMed: 22416173]
  24. Bonomo G, Della Vigna P, Monfardini L, Orgera G, Orsi F. Micro-bland embolization (mb-TAE) may enhance local outcome of RFA in the treatment of complex liver metastases from CRC. CardioVascular and Interventional Radiology. 2011;34:603.
  25. Boone BA, Bartlett DL, Zureikat AH. Isolated Hepatic Perfusion for the Treatment of Liver Metastases. Current Problems in Cancer. 2012;36(2):27–76. [PubMed: 22464447]
  26. Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, Noya G, Abraha I. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;6:CD006317. [PubMed: 22696357]
  27. Cohen SJ, Konski AA, Putnam S, Ball D, Meyer JE, Yu JQ, Astsaturov IA, Magalong K, Cade D, Meropol NJ. A phase I study of capecitabine in combination with yttrium-90 labeled resin microspheres (SIR-Spheres) in patients (pts) with advanced cancer. Journal of Clinical Oncology. 2011;29(15) [PMC free article: PMC4102951] [PubMed: 24983373]
  28. Cosimelli M, Mancini R, Carpanese L, Sciuto R, Pizzi G, Pattaro G, Maini CL. Integration of radioembolisation into multimodal treatment of liver-dominant metastatic colorectal cancer. Expert Opin Ther Targets. 2012;16 Suppl 2:S11–6. [PubMed: 22443155]
  29. Dawson LA, Swaminath A, Massey C, Kim J, Diniwell R, Brierley J, Wong R, Velec M, Brock K. Stereotactic radiotherapy for liver metastases. European Journal of Cancer. 2011;47:S89.
  30. De Baere T. Transcatheter therapy in hepatic colorectal metastasis has value. CardioVascular and Interventional Radiology. 2011;34:482–483.
  31. Ducreux M, Rougier P, Smith D, Focan CNJ, Innominato PF, Bouchahda M, Ajavon Y, Castaing D, De Baere T, Karaboue A, Lepere C, Boige V, Adam R, Levi F. Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II trial. Journal of Clinical Oncology. 2011;29(15)
  32. Evrard S, Rivoire M, Arnaud JP, Lermite E, Bellera C, Mathoulin-Pelissier S, Fonck M, Brunet R, Becouarn Y, Lalet C. Unresectable colorectal liver metastases treated by intraoperative radiofrequency ablation with or without resection: the ARF2003 study. European Journal of Cancer. 2011;47:S393.
  33. Fiorentini G, Aliberti C, Tilli M, Mambrini A, Turrisi G, Dentico P, Benea G. Evaluation of a phase III clinical trial comparing transarterial chemoembolisation (TACE) using irinotecaN-loaded polyvinyl alcohol micrOsperes (Debiri) vs systemic chemotherapy Folfiri (CT) for the treatment of unresectable metastases to the liver (LM) in patients with advanced colorectal cancer (MCRC). CardioVascular and Interventional Radiology. 2011;34:599.
  34. Magge D, Zureikat A, Bartlett D, Holtzman M, Choudry H, Beumer J, Holleran JL, Strychor S, Pingpank J, Zeh HJ. A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases (ILM) from colorectal cancer (CRC). Annals of Surgical Oncology. 2012;19:S115. [PMC free article: PMC3808182] [PubMed: 23575907]
  35. Nishiofuku H, Tanaka T, Anai H, Sueyoshi S, Matsuoka M, Otsuji T, Yamamoto K, Inaba Y, Sakaguchi H, Kichikawa K. Phase I/II study of transcatheter arterial chemoembolization with cisplatin powder and degradable starch microspheres for unresectable hepatic metastases from colorectal cancer refractory to systemic standard chemotherapy. Journal of Clinical Oncology. 2011;29(4)
  36. Orsi F, Bonomo G, Della Vigna P, Monfardini L. Combination therapy. CardioVascular and Interventional Radiology. 2011;34:365–366.
  37. Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis. 2012 [PubMed: 22358385]
  38. Rose SC, Roeland E, Shimabukuro K, Fanta P, Parker B, Kono Y, Reid T. Single center prospective phase II trial of Yttrium-90 radioembolization for treatment of colorectal liver metastases that have failed first line chemotherapy and prior to initiation of second line chemotherapy: Study design and early results. CardioVascular and Interventional Radiology. 2011;34:502.
  39. Scorsetti M, Castiglioni S, Tozzi A, Alongi F, Pentimalli S, Ascolese A, Navarria P, Arcangeli S, Mancosu P, Cozzi L. SBRT dose escalation Phase II study for liver metastases using volumetric modulated Arc therapy (VMAT-RapidArc). International Journal of Radiation Oncology Biology Physics. 2011;81(2):S346.
  40. Shimada Y. Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective. J Hepatobiliary Pancreat Sci. 2012:1–8. [PubMed: 22588204]
  41. Sobrero A, Di Benedetto M. Neoadjuvant treatment in colon cancer. European Journal of Cancer. 2011;47:S72–S73.
  42. Stein A, Duex M, Kickuth R, Petrovitch A, Pluntke S, Ricke J, Stroszczynski C, Vogl TJ, Arnold D, Pereira PL. A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory colorectal liver metastases and Kras wild-type tumors. CardioVascular and Interventional Radiology. 2011;34:617.

Level 3, Form CRC Full-textScreening, Animal study -> Exclude

  1. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91. [PubMed: 19255313]

Level 3, Form CRC Full-textScreening, Not Relevant Population -> Exclude

  1. Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010;9(5):311–4. [PMC free article: PMC3088086] [PubMed: 21208846]
  2. Khouri C, Guiu B, Cercueil JP, Chauffert B, Ladoire S, Ghiringhelli F. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs. 2010;21(6):656–61. [PubMed: 20216061]
  3. Cianni R, Urigo C, Notarianni E, Saltarelli A, D’Agostini A, Iozzino M, Dornbusch T, Cortesi E. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med. 2010;115(4):619–33. [PubMed: 20091135]
  4. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171–8. [PubMed: 19707829]
  5. Meijerink MR, van den Tol P, van Tilborg AA, van Waesberghe JH, Meijer S, van Kuijk C. Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: initial clinical experience. Eur J Radiol. 2011;77(1):167–71. [PubMed: 19616911]
  6. Knudsen AR, Kannerup AS, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiol. 2009;50(7):716–21. [PubMed: 19488894]
  7. Poggi G, Quaretti P, Minoia C, Bernardo G, Bonora MR, Gaggeri R, Ronchi A, Saluzzo CM, Azzaretti A, Rodolico G, Montagna M, Amatu A, Teragni C, Palumbo I, Traverso E, Tonini S, Villani L, Scelsi M, Baiardi P, Felisi MG, Sottotetti F, Tagliaferri B, Riccardi A. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res. 2008;28(6B):3835–42. [PubMed: 19192637]
  8. Zeh HJ 3rd, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, Potter DM, Bartlett DL. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2009;16(2):385–94. [PubMed: 19034580]
  9. Hofer S, Oberholzer C, Beck S, Looser C, Ludwig C. Ultrasound-guided radiofrequency ablation (RFA) for inoperable gastrointestinal liver metastases. Ultraschall Med. 2008;29(4):388–92. [PubMed: 18785319]
  10. Jagad RB, Koshariya M, Kawamoto J, Papastratis P, Kefalourous H, Patris V, Porfiris T, Gevrielidis P, Tzouma C, Lygidakis NJ. Laparoscopic microwave ablation of liver tumors: our experience. Hepatogastroenterology. 2008;55(81):27–32. [PubMed: 18507073]
  11. Hildebrand P, Kleemann M, Roblick U, Mirow L, Birth M, Bruch HP. Laparoscopic radiofrequency ablation of unresectable hepatic malignancies: indication, limitation and results. Hepatogastroenterology. 2007;54(79):2069–72. [PubMed: 18251161]
  12. Liepe K, Brogsitter C, Leonhard J, Wunderlich G, Hliscs R, Pinkert J, Folprecht G, Kotzerke J. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. Jpn J Clin Oncol. 2007;37(12):942–50. [PubMed: 18094017]
  13. Schumacher G, Eisele R, Spinelli A, Schmidt SC, Jacob D, Pratschke J, Neuhaus P. Indications for hand-assisted laparoscopic radiofrequency ablation for liver tumors. J Laparoendosc Adv Surg Tech A. 2007;17(2):153–9. [PubMed: 17484640]
  14. Ritz JP, Lehmann KS, Zurbuchen U, Wacker F, Brehm F, Isbert C, Germer CT, Buhr HJ, Holmer C. Improving laser-induced thermotherapy of liver metastases--effects of arterial microembolization and complete blood flow occlusion. Eur J Surg Oncol. 2007;33(5):608–15. [PubMed: 17400421]
  15. Low SC, Lo RH, Lau TN, Ooi LL, Ho CK, Tan BS, Chung AY, Koo WH, Chow PK. Image-guided radiofrequency ablation of liver malignancies: experience at Singapore General Hospital. Ann Acad Med Singapore. 2006;35(12):851–7. [PubMed: 17218995]
  16. Geyik S, Akhan O, Abbasoglu O, Akinci D, Ozkan OS, Hamaloglu E, Ozmen M. Radiofrequency ablation of unresectable hepatic tumors. Diagn Interv Radiol. 2006;12(4):195–200. [PubMed: 17160805]
  17. Krishnan S, Lin EH, Gunn GB, Chandra A, Beddar AS, Briere TM, Das P, Delclos ME, Janjan NA, Crane CH. Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases. Am J Clin Oncol. 2006;29(6):562–7. [PubMed: 17148992]
  18. Cosin O, Bilbao JI, Alvarez S, de Luis E, Alonso A, Martinez-Cuesta A. Right gastric artery embolization prior to treatment with yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2007;30(1):98–103. [PubMed: 17031727]
  19. Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, Madoff DC, Gupta S, Wallace MJ, Ahrar K, Hicks ME. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol. 2005;16(7):937–45. [PubMed: 16002501]
  20. Gulec SA, Mountcastle TS, Frey D, Cundiff JD, Mathews E, Anthony L, O’Leary JP, Boudreaux JP. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg. 2002;68(8):667–71. discussion 671–2. [PubMed: 12206599]
  21. Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF. Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol. 2002;8(4):624–30. [PMC free article: PMC4656310] [PubMed: 12174368]
  22. Isambert N, Correia M, Cercueil JP, Zanetta S, Osmak L, Flesch M, Krause D, Coudert B, Fargeot P, Bedenne L, Chauffert B. Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study. J Exp Clin Cancer Res. 2001;20(2):183–8. [PubMed: 11484972]
  23. Skalicky T, Treska V, Sutnar A, Liska V, Duras P, Slauf F. Chemo-embolization of inoperable liver tumors. Bratisl Lek Listy. 2010;111(12):676–9. [PubMed: 21384740]
  24. Fiorentini G, Aliberti C, Benea G, Montagnani F, Mambrini A, Ballardini PL, Cantore M. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology. 2008;55(88):2077–82. [PubMed: 19260480]
  25. Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, Wikler D, Gelin M. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol. 2003;84(4):215–23. [PubMed: 14756432]
  26. Gulec SA, Suthar RR, Barot TC, Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38(7):1289–95. [PubMed: 21461737]
  27. Samaras P, Breitenstein S, Haile SR, Stenner-Liewen F, Heinrich S, Feilchenfeldt J, Renner C, Knuth A, Pestalozzi BC, Clavien PA. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Ann Surg Oncol. 2011;18(7):1924–31. [PubMed: 21207165]
  28. Bowling JT, Reuter NP, Martin RCG, McMasters KM, Tatum C, Scoggins CR. Prior biliary tree instrumentation does not preclude hepatic arterial therapy for malignancy. American Surgeon. 2010;76(6):618–621. [PubMed: 20583518]
  29. Hildebrand P, Leibecke T, Kleemann M, Mirow L, Birth M, Bruch HP, Burk C. Influence of operator experience in radiofrequency ablation of malignant liver tumours on treatment outcome. European Journal of Surgical Oncology. 2006;32(4):430–434. [PubMed: 16520015]
  30. Hildebrand P, Kleemann M, Roblick UJ, Mirow L, Birth M, Leibecke T, Bruch HP. Radiofrequency-ablation of unresectable primary and secondary liver tumors: Results in 88 patients. Langenbeck’s Archives of Surgery. 2006;391(2):118–123. [PubMed: 16604376]
  31. Melichar B, Touskova M, Blaha M, Vesely P, Dvorak J, Krajina A, Cerman J Jr. Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biotherapy and Radiopharmaceuticals. 2002;17(5):545–552. [PubMed: 12470424]
  32. Votrubova J, Horejs J, Peskova M, Svab J, Krska Z. Radiofrequency thermoablation of hepatic tumours. Ceska Radiologie. 2002;56(3):145–150.
  33. Bhat J, Habr F. Photodynamic therapy in nonresectable cholangiocarinoma-is it worth it? American Journal of Gastroenterology. 2011;106:S56–S57.
  34. Boda-Heggemann J, Dinter D, Weiss C, Siebenlist K, Attenberger U, Frauenfeld A, Ottstadt M, Simeonova A, Schneider F, Hofheinz R, Lohr F, Wenz F. Hypofractionated image-guided breath-hold radiotherapy of liver metastases - Clinical results. Strahlentherapie und Onkologie. 2011;187:19.
  35. Bonomo G, Della Vigna P, Monfardini L, Orgera G, Chiappa A, Bianchi PP, Zampino MG, Orsi F. Combined Therapies for the Treatment of Technically Unresectable Liver Malignancies: Bland Embolization and Radiofrequency Thermal Ablation within the Same Session. Cardiovasc Intervent Radiol. 2012 [PubMed: 22271077]
  36. Engels B, Gevaert T, Everaert H, De Coninck P, Sermeus A, Christian N, Storme G, Verellen D, De Ridder M. Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. Radiat Oncol. 2012;7:34. [PMC free article: PMC3355052] [PubMed: 22423615]
  37. House MG, Kemeny NE, Gonen M, Fong Y, Allen PJ, Paty PB, DeMatteo RP, Blumgart LH, Jarnagin WR, D’Angelica MI. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254(6):851–6. [PubMed: 21975318]
  38. Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, Hegarty B, Brown K, Steward WP, Gescher AJ. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila). 2011;4(9):1419–25. [PMC free article: PMC3173869] [PubMed: 21680702]
  39. Kim YC, Kim YH, Um SH, Seo YS, Park EK, Oh SY, Han YM, Choe JG. Usefulness of bremsstrahlung images after intra-arterial Y-90 resin microphere radioembolization for hepatic tumors. Nuclear Medicine and Molecular Imaging. 2011;45(1):59–67. [PMC free article: PMC4042949] [PubMed: 24899979]
  40. Martin RC 2nd, Scoggins CR, Tomalty D, Schreeder M, Metzger T, Tatum C, Sharma V. Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial. J Gastrointest Surg. 2012 [PubMed: 22528576]
  41. Reissfelder C, Timke C, Schmitz-Winnenthal H, Rahbari NN, Koch M, Klug F, Roeder F, Edler L, Debus J, Buchler MW, Beckhove P, Huber PE, Weitz J. A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer. 2011;11:419. [PMC free article: PMC3195202] [PubMed: 21961577]
  42. Simoneau E, Aljiffry M, Salman A, Abualhassan N, Cabrera T, Valenti D, El Baage A, Jamal M, Kavan P, Al-Abbad S, Chaudhury P, Hassanain M, Metrakos P. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford). 2012;14(7):461–8. [PMC free article: PMC3384876] [PubMed: 22672548]

Level 3, Form CRC Full-textScreening, Not Relevant Intervention -> Exclude

  1. Van Tilborg AA, Meijerink MR, Sietses C, Van Waesberghe JH, Mackintosh MO, Meijer S, Van Kuijk C, Van Den Tol P. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 2011;841002:556–65. [PMC free article: PMC3473628] [PubMed: 21159807]
  2. Chen Y, Yan Z, Wang J, Wang X, Luo J, Liu Q. Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. Anticancer Res. 2010;30(7):3045–9. [PubMed: 20683053]
  3. Yamaguchi T, Matsumoto H, Yasutome M, Mori T, Takahashi K. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. Cancer Chemother Pharmacol. 2011;67(3):629–35. [PubMed: 20495917]
  4. Martin RC, Robbins K, Tomalty D, O’Hara R, Bosnjakovic P, Padr R, Rocek M, Slauf F, Scupchenko A, Tatum C. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009;7:80. [PMC free article: PMC2777901] [PubMed: 19886993]
  5. Wieners G, Pech M, Hildebrandt B, Peters N, Nicolaou A, Mohnike K, Seidensticker M, Sawicki M, Wust P, Ricke J. Phase II feasibility study on the combination of two different regional treatment approaches in patients with colorectal “liver-only” metastases: hepatic interstitial brachytherapy plus regional chemotherapy. Cardiovasc Intervent Radiol. 2009;32(5):937–45. [PubMed: 19472000]
  6. Verhoef C, de Wilt JH, Brunstein F, Marinelli AW, van Etten B, Vermaas M, Guetens G, de Boeck G, de Bruijn EA, Eggermont AM. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol. 2008;15(5):1367–74. [PMC free article: PMC2277449] [PubMed: 18239976]
  7. Gallagher DJ, Capanu M, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol. 2007;18(12):1995–9. [PubMed: 17962209]
  8. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–26. [PubMed: 17896145]
  9. Pech M, Wieners G, Freund T, Dudeck O, Fischbach F, Ricke J, Seemann MD. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. Eur J Med Res. 2007;12(4):161–8. [PubMed: 17509960]
  10. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106. [PubMed: 17369573]
  11. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65(2):412–25. [PubMed: 16690429]
  12. Martin RC 2nd, Scoggins CR, McMasters KM. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy. J Surg Oncol. 2006;93(5):387–93. [PubMed: 16550574]
  13. van Duijnhoven FH, Rovers JP, Engelmann K, Krajina Z, Purkiss SF, Zoetmulder FA, Vogl TJ, Terpstra OT. Photodynamic therapy with 5,10,15,20-tetrakis(m-hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: results from a phase I study. Ann Surg Oncol. 2005;12(10):808–16. [PubMed: 16132377]
  14. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23(22):4881–7. [PubMed: 16009952]
  15. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, Leonard G, D’Angelica M, DeMatteo R, Blumgart L, Fong Y. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888–96. [PubMed: 16009951]
  16. Morgan JH 3rd, Royer GM, Hackett P, Gamblin TC, McCampbell BL, Conforti A, Dale PS. Radio-frequency ablation of large, nonresectable hepatic tumors. Am Surg. 2004;70(12):1035–8. [PubMed: 15663040]
  17. van Etten B, Brunstein F, van IMG, Marinelli AW, Verhoef C, van der Sijp JR, Guetens G, de Boeck G, de Bruijn EA, de Wilt JH, Eggermont AM. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. Ann Surg Oncol. 2004;11(6):598–605. [PubMed: 15172933]
  18. Tepel J, Hinz S, Klomp HJ, Kapischke M, Kremer B. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. Eur J Surg Oncol. 2004;30(5):551–5. [PubMed: 15135485]
  19. Onaitis M, Morse M, Hurwitz H, Cotton P, Tyler D, Clavien P, Clary B. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg. 2003;237(6):782–8. discussion 788–9. [PMC free article: PMC1514694] [PubMed: 12796574]
  20. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J, Tong W, Paty P. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19(10):2687–95. [PubMed: 11352961]
  21. Baumgart J, Lang S, Lang H. A new method for induction of liver hypertrophy prior to right trisectionectomy: A report of three cases. HPB. 2011;13:71–72.
  22. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535–46. [PubMed: 21228335]
  23. Bruera G, Cannita K, Giuliante F, Baldi PL, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer. 2012;11(2):119–26. [PubMed: 22206922]
  24. Bruera G, Cannita K, Lanfiuti Baldi P, Santomaggio A, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Effectiveness of FIr-B/FOx and liver metastasectomies in liver-only metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 2011;29(4)
  25. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105(1):58–64. [PMC free article: PMC3137415] [PubMed: 21673685]
  26. Fornaro L, Loupakis F, Lonardi S, Masi G, Salvatore L, Cremolini C, Bergamo F, Cappetta A, Zagonel V, Falcone A. FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in combination with panitumumab (P) in the first-line treatment of metastatic colorectal cancer (mCRC) patients (PTS) selected for KRAS, BRAF, nras and hras mutational status? A Phase II study by the G.O.N.O. group. European Journal of Cancer. 2011;47:S420.
  27. Frank M, Asseburg C, Kohne CH, Hartmann JT, Schulten J, Mohr A, Mittendorf T. Exploring the cost-effectiveness of targeted therapy with cetuximab vs bevacizumab in Germany in patients with KRAS wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver. Onkologie. 2011;34:246. [PubMed: 21635994]
  28. Galal KM, Khaled Z, Mourad AM. Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer. 2011;48(1):47–54. [PubMed: 21248446]
  29. Goi T, Sawai K, Koneri K, Katayama K, Yamaguchi A. Results of hepatic arterial infusion chemotherapy in patients with unresectable liver metastases. Viszeralmedizin: Gastrointestinal Medicine and Surgery. 2011;27(5):397–401.
  30. Hur H, Kim NK, Kim HG, Min BS, Lee KY, Shin SJ, Cheon JH, Choi SH. Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. Br J Cancer. 2012;106(1):53–60. [PMC free article: PMC3251844] [PubMed: 22068817]
  31. Kataoka K, Kanazawa A, Nakajima A, Yamaguchi A, Tuyuki S, Arimoto A, Kohno Y. Feasibility and potential benefit of neoadjuvant chemotherapy for colorectal liver metastasis: A single-centered retrospective study. Journal of Clinical Oncology. 2011;29(4) [PubMed: 23139049]
  32. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP, D’Angelica MI. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol. 2011;29(7):884–9. [PMC free article: PMC3646323] [PubMed: 21189384]
  33. Liska V, Sutnar A, Jr LH, Vrzalova J, Treska V, Skalicky T, Pesta M, Kormunda S, Finek J, Rousarova M, Topolcan O. Matrix metalloproteinases and their inhibitors in correlation to proliferative and classical tumour markers during surgical therapy of colorectal liver metastases. Bratisl Lek Listy. 2012;113(2):108–13. [PubMed: 22394042]
  34. Muratore A, Zimmitti G, Ribero D, Mellano A, Vigano L, Capussotti L. Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it? Ann Surg Oncol. 2012;19(4):1310–5. [PubMed: 21947627]
  35. Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. Int J Clin Oncol. 2012 [PubMed: 22383023]
  36. Tanaka K, Kumamoto T, Nojiri K, Takeda K, Endo I. Postchemotherapy histological analysis of major intrahepatic vessels for reversal of attachment or invasion by colorectal liver metastases. Cancer. 2012;118(9):2443–2453. [PubMed: 21953291]
  37. Uehara K, Ishiguro S, Hiramatsu K, Nishio H, Takeuchi E, Takahari D, Yoshioka Y, Takahashi Y, Ebata T, Yoshimura K, Muro K, Nagino M. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer. Jpn J Clin Oncol. 2011;41(10):1229–32. [PubMed: 21840871]
  38. Uetake H, Tanaka S, Ishikawa T, Sugihara K, Arii S. Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions. J Hepatobiliary Pancreat Sci. 2012 [PubMed: 22539087]

Level 3, Form CRC Full-textScreening, Not Relevant Outcome -> Exclude

  1. Poggi G, Quaretti P, Montagna B, Sottotetti F, Tagliaferri B, Pozzi E, Amatu A, Pagella C, Bernardo G. Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization. Cardiovasc Intervent Radiol. 2011;34 Suppl 2:S190–4. [PubMed: 20848100]
  2. Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P, Casamassima F, Febbraro A, Gerunda G, Lumachi F. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009;29(8):3381–4. [PubMed: 19661360]
  3. Murthy R, Eng C, Krishnan S, Madoff DC, Habbu A, Canet S, Hicks ME. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. J Vasc Interv Radiol. 2007;18(12):1588–91. [PubMed: 18057297]
  4. Ritz JP, Lehmann KS, Reissfelder C, Albrecht T, Frericks B, Zurbuchen U, Buhr HJ. Bipolar radiofrequency ablation of liver metastases during laparotomy. First clinical experiences with a new multipolar ablation concept. Int J Colorectal Dis. 2006;21(1):25–32. [PubMed: 15875202]
  5. Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35(4):222–7. [PubMed: 15836500]
  6. Basdanis G, Michalopoulos A, Papadopoulos V, Tzeveleki I, Efthimiadis C, Kosmidis C, Mekras D, Harlaftis N. Clinical short-term results of radiofrequency ablation in patients with liver metastases from colorectal cancer. Tech Coloproctol. 2004;8 Suppl 1:s187–9. [PubMed: 15655617]
  7. Bachar GN, Greif F, Mor E, Tur-Kaspa R, Belenky A. Radiofrequency ablation for the management of liver tumors. Isr Med Assoc J. 2003;5(7):496–500. [PubMed: 12901246]
  8. Tanaka T, Arai Y, Inaba Y, Matsueda K, Aramaki T, Takeuchi Y, Kichikawa K. Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol. 2003;14(1):63–8. [PubMed: 12525587]
  9. Mallach S, Ramp U, Erhardt A, Schmitt M, Haussinger D. An uncommon cause of gastro-duodenal ulceration. World J Gastroenterol. 2008;14(16):2593–5. [PMC free article: PMC2708377] [PubMed: 18442213]
  10. Mancini R, Carpanese L, Sciuto R, Pizzi G, Golfieri R, Giampalma L, Cappelli A, Galaverni MC, Blotta A, Fiore F, Izzo F, Lastoria S, Mastro A, Di Marzo M, Cagol PP, Gasparini D, Geatti O, Bacchetti S, Pasqual E, Zeuli M, Paoletti G, Garufi C, Cosimelli M. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates. In Vivo. 2006;20(6A):711–4. [PubMed: 17203751]
  11. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010 Aug 10;28(23):3687–94. [PubMed: 20567019]
  12. Evrard S, Rivoire M, Arnaud J, Lermite E, Bellera C, Fonck M, Becouarn Y, Lalet C, Puildo M, Mathoulin-Pelissier S. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg. 2012;99(4):558–65. [PubMed: 22396054]
  13. Lauenstein TC, Heusner TA, Hamami M, Ertle J, Schlaak JF, Gerken G, Bockisch A, Antoch G. Radioembolization of hepatic tumors: Flow redistribution after the occlusion of intrahepatic arteries. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren. 2011;183(11):1058–1064. [PubMed: 21959887]
  14. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006;26(5B):3793–5. [PubMed: 17094403]
  15. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15(1):219–26. [PubMed: 17896145]
  16. Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W, Tatsch K, Lubiensky A, Reiser MF, Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol. 2007;17(5):1320–30. [PubMed: 17149621]
  17. Veltri A, Sacchetto P, Tosetti I, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol. 2008 Sep–Oct;31(5):948–56. [PubMed: 18506519]
Copyright Notice
Bookshelf ID: NBK115714
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.3M)

In this Page

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...